Early detection and treatment strategies for vulnerable atherosclerotic plaques by Pham, Tuan A.
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2015
Early detection and treatment
strategies for vulnerable
atherosclerotic plaques
https://hdl.handle.net/2144/15207
Boston University
	  BOSTON UNIVERSITY 
 
COLLEGE OF ENGINEERING 
 
 
 
 
 
Dissertation 
 
 
 
 
 
EARLY DETECTION AND TREATMENT STRATEGIES FOR 
 
VULNERABLE ATHEROSCLEROTIC PLAQUES 
 
 
 
 
by 
 
 
 
 
TUAN ANH PHAM 
 
B.Sc., University of Massachusetts, Amherst, 2008 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Doctor of Philosophy 
 
2015  
	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	   © 2015 by 
  TUAN ANH PHAM 
  All rights reserved  

	  	  iv 
Dedication	  
 
I dedicate my dissertation work to my friends and family, all of which have supported 
and guided me throughout my tenure at Boston University.  Specifically, my mother, who 
has always been there to encourage, support and guide me through the tough times as 
well as share with me the joyous occasions. 
I also dedicate this work to my brother, Vu Pham, for his support and ears throughout the 
rough, final year of my dissertation and to my friend, Chaumy Diep, for his moral 
support, the confidence he has instilled in me and the late night logical conversations that 
eased my mind throughout the years.  
	  	  v 
Acknowledgments 
 
I would like to thank my advisors Dr. James A. Hamilton and Dr. Joyce Y Wong for all 
of their guidance and support throughout my dissertation.  I would also like to thank both 
the Wong and Hamilton lab members for their help and advice on projects.  Specifically 
Yoonjee Park for her help with the microbubble work and Ning Hua for her help on the 
rabbit projects.  A special thank you to Alkystis Phinikaridou for email support even after 
graduating and moving out of the country. 
I would like to thank the members of the Forsyth Institution; Dr. Hatice Hasturk, Dr. 
Alpdogan Kantarci and Dr. Thomas Van Dyke; for their collaboration and assistance with 
the Lipoxin work.  Additional thanks to Jon Nagy for providing the lipids and making 
himself extremely available for questions during my microbubble work time. 
I give special thanks to Dr. Edward Damiano for the exchanges in emails and a phone 
call that changed my life in 2008 prior to entering the program and for the additional 
academic advising he provided me in the early years of my candidacy.  Finally, I would 
like to thank my colleagues; Ning Hua, Shamit Shrivastava and Daniel Backman, for all 
of their help ranging from classwork to experimentation and for the endless hours of 
coffee and tea that we have shared, all of which ensured my sanity.  
 
  
	  	  vi 
EARLY DETECTION AND TREATMENT STRATEGIES FOR 
 
VULNERABLE ATHEROSCLEROTIC PLAQUES 
 
TUAN ANH PHAM 
 
Boston University College of Engineering, 2015 
Major Professors: James A. Hamilton, Ph.D., Professor of Physiology and Biophysics,  
 Professor of Biomedical Engineering, Research Professor of  
 Medicine 
 
 and  
 
 Joyce Y. Wong, Ph.D., Professor of Biomedical Engineering 
 
ABSTRACT 
 
Atherosclerotic plaque ruptures have been determined as the most common underlying 
cause of acute coronary syndromes and stroke.  Currently, the standard of care for plaque 
rupture risk is based on the amount of luminal stenosis presented in a particular vessel; 
however, X-ray angiographic studies have shown that plaques at risk of rupture generally 
show <50% luminal narrowing.  These findings explicate the need for other, more 
accurate methods of identifying problem lesions prior to the rupture event.  
Unfortunately, the study of thrombotic events and vulnerable plaque lesions in humans is 
difficult due to the spontaneity of rupture and the lengthy time course of disease 
progression.  To further the understanding of plaque rupture risk in light of vulnerability 
detection, a rabbit model of atherothrombosis was used in conjunction with magnetic 
resonance imaging (MRI).  MRI has been validated as a suitable imaging modality for in 
vivo, non-invasive detection of atherosclerosis and has provided quantitative predictors 
of plaques at risk of rupture.  Additionally, the rabbit model has been shown, 
	  	  vii 
histologically, to present 6 of the 8 human plaque types classified by the American Heart 
Association.  
The first portion of this dissertation work focuses on using MRI to serially image rabbits 
undergoing the atherosclerotic protocol in order to assess rupture risk at the various time 
points.  Previous work has determined that an increase in the vessel remodeling ratio 
(which hides a large plaque in the vessel wall) and contrast uptake (which indicates 
inflammation) are both characteristics of increased rupture risk.  By obtaining these 
parameters at various time points in the disease progression, it was possible to determine 
when a certain plaque displays a heightened risk of rupture.  The second portion of this 
work tested the efficacy of a pro-resolving molecule, lipoxin (an endogenous molecule), 
in reducing atherosclerotic disease state, specifically rupture with a luminal thrombus.  
Using chronic administration of this molecule in the same rabbit model of atherosclerosis 
yielded a faint reduction in atherosclerotic severity based on the parameters of decreased 
vessel lipid content and decreased thrombotic events presented in the treated group.   
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Chapter 1:  Introduction and Thesis Aims 
	  
1.1 Overarching Goals and Thesis Aims 
The purpose of this thesis work was to monitor development of vulnerable (at-risk) 
atherosclerotic plaques over time in rabbit model of atherothrombosis and test therapies 
to attenuate plaque severity and disruption.  To achieve this goal, three aims were 
proposed as follows: 
Specific Aim 1: Establishing hallmarks of plaque vulnerability in an animal model. 
Using a rabbit model of controlled atherothrombosis, we explored the progression of said 
atherosclerosis from inception to the end of a 3 month protocol, sometimes resulting in 
plaque rupture with subsequent thrombosis.  By employing magnetic resonance imaging 
scans at specific time points (baseline, 1 month, 2 months and 3 months into the 
protocol), we were able to track the progression of atherosclerosis in these rabbits.  We 
used image post processing to determine features associated with plaques that ultimately 
rupture and discovered that aortic vessel wall size, aortic remodeling ratio and degree of 
gadolinium contrast uptake were all associated with plaques that rupture. 
Aim 2: Testing the ability of Lipoxin A4 in reducing said hallmarks, and 
determining effects on plaque rupture rate  
The same rabbit model of controlled atherothrombosis was used to test the effects of an 
inflammation resolution molecule, Lipoxin A4, on the hallmarks of plaque vulnerability 
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established in Aim 1.  Additionally, special attention was given to the effects of Lipoxin 
on the rupture rate of plaques. 
Specific Aim 3:  Developmental work on theranostic ultrasound contrast agents 
(microbubbles). 
Polymerizable diacetylene lipids were used to perform 2 tasks i) testing the effects of 
vortexing vs. microfluidic flow-focusing on the integrity of oil droplets and ii) creating a 
pilot drug carrying, tunable, theranostic microbubble. 
The first portion of this aim used vortexing and microfluidic flow-focusing to create lipid 
coated oil droplets and measured each formulation’s stability.  Since theranostic 
microbubbles are generally formed with one of these two methods, it was important to 
test the stability differences between the methods.  This study showed that flow-focused 
oil droplets were more stable, which lead to the use of flow-focusing for the second part 
(ii) of this aim. 
We developed monodisperse, tunable, targeted, gas filled lipid microbubbles with anti-
angiogenesis drugs encapsulated inside using microfluidic flow-focusing for image 
enhancement and controlled drug release. Using a microfluidic device, we made 
monodisperse gas filled lipid microbubbles, which will provide a more accurate 
echogenic profile as compared to polydisperse bubbles. We were also be able to 
incorporate drugs, (paclitaxel and doxorubicin) into the bubble and tune the ‘burstability’ 
of these bubbles via ultrasound probe by using special polymerizable lipids in the lipid 
monolayer.  
	  	  
3 
The goal of this particular aim was to lay the groundwork for future projects to include a 
theranostic microbubble with magnetic resonance imaging contrast and inflammation 
resolving molecules in it to detect and treat atherosclerosis.  
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1.2 Brief Introduction on Atherosclerosis  
Atherosclerosis is a chronic inflammatory disease which causes thickening of the artery 
walls due to the accumulation of lipids [1], among other cellular components [2, 3].  This 
accumulation forms a plaque, which increases slowly in size over time.  In adulthood, 
plaques can occlude the vessel, and reduce blood flow through   the lumen. Although 
occlusion is cause for concern, it often produces symptoms of ischemia that lead to its 
detection and treatment, often by stenting to restore good blood flow, before it causes a 
fatal event. This type of plaque falls into the general category of “stable.”  A more 
dangerous consequence of plaque development occurs when it leads to a plaque with 
lower stenosis, but in highly inflamed state that causes it to disrupt, usually without 
warning,  to form a luminal thrombus, which can lead to myocardial events such as stroke 
and infarction [4, 5].  These acute coronary syndromes are among the leading causes of 
death in the United States, causing over half a million deaths a year [6].  
Human plaques have been classified by the American Heart Association (AHA) into 6 
categories (Types I-VI) based on morphology and plaque constituents [7, 8].  The 
progression from clinically silent plaques (Types I and II) to more advanced, vulnerable 
of disruption, plaques (Type VI) occurs slowly through decades of chronic inflammation. 
It is has been widely accepted that the initial lesions (type I) of aortic plaques occurs with 
the passive diffusion of low-density lipoproteins (LDL) into the vessel wall [9].  The 
trapped LDL undergoes oxidation, triggering recruitment of monocytes to the area [10].  
These monocytes then differentiate into macrophages and become foam cells [11].  This 
process causes the inhibition of cholesterol removal from the aortic wall while cholesterol 
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uptake continues [12].  As this cascade continues, the number of individual foam cells 
increases and start to form layers (type II) of foam cells.  These first two types of plaques 
are clinically silent and usually do not cause aortic stenosis.  Type III plaques occur as 
the disease progresses.  Small extracellular lipid pockets start to form and tissue 
degradation is present.  Additionally, there is an increase in free cholesterol, 
phospholipids and triglycerides [1]. 
Of more interest are the more advanced lesions (types IV-VI).  Once the small lipid 
pockets start to consolidate into a lipid core, then the plaque is classified as type IV.  
Although type IV plaques do not cause severe luminal narrowing, the surface 
composition of these lesions make them susceptible to rupture; possibly transforming a 
type IV plaque into a type VI plaque [7].  Type V lesions have larger lipid or necrotic 
cores and can cause severe stenosis of the blood vessel; however, if there is enough 
collateral blood flow as to prevent ischemia, then these lesions are also clinically silent.  
As with type IV lesions, type V lesions can also have surface defects or erosion of the 
fibrous cap causing plaque rupture and subsequent type VI classification.  Once a plaque 
ruptures and causes thrombus formation or hematoma, it is classified as a type VI plaque.  
A summary of these plaque classifications is shown in Table 1.   
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Table 1:  AHA classification of atherosclerotic plaques.  Adapted from Stary et al. 
[7]. 
Plaque Type Properties 
I Initial Lesions Isolated macrophage foam cells. 
II Fatty Streak Lesions Macrophage foam cells forming layers. 
III Intermediate 
Lesions 
Type II + extracellular lipid pools and tissue 
degradation. 
IV Atheroma Lesions 
Large extracellular lipid cores exist and fibrous cap 
formation. 
V Fibroatheroma 
Lesions 
Calcium deposition, necrotic core, and accelerated 
smooth muscle and collagen increase. 
VI Complicated 
Lesions 
Surface defects, thrombosis and hematoma. 
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In accordance with the progression of the disease, current care standards typically use the 
degree of arterial stenosis as a diagnostic marker for amount of clinical danger that a 
specific plaque poses.  However, studies have shown that acute cardiovascular events that 
typically lead to a severe clinical outcome (myocardial infarction, stroke, death etc.) are a 
result of plaques that rupture (type VI plaques) and cause spontaneous and abrupt 
thrombosis.  Plaque composition was found to play a more definitive role in plaque 
vulnerability [13, 14] than the degree of stenosis and plaque size [15].  In fact, the 
majority of plaques that advance to type VI (ruptured) were found to have <50% luminal 
narrowing [16, 17].  These findings have been the motivation behind the growing number 
of studies focused on plaque disruption (erosion or rupture) as an experimental endpoint 
[18].   
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1.3 MRI of Atherosclerosis 
In an effort to improve the standard of care of atherosclerosis, specifically plaque rupture 
risk, many groups have used a variety of imaging modalities to try and elucidate 
properties of vulnerable plaques.  The idea behind this is to determine characteristics of 
plaques via non-invasive imaging that are predictive of plaque rupture.  Having such 
information would allow clinicians to prescribe prevention and/or intervention of plaque 
rupture.  Additionally, having a plaque deemed as at-risk for rupture could also give the 
patient an idea of how much monitoring they should be receiving. This is a challenging 
task because the dangerous plaques are in a diseased vessel with multiple stages of 
plaques, and the method must discriminate such plaques from those that are expected to 
remain stable.  
Many imaging modalities have been used to characterize plaques including positron-
emission tomography (PET) [19], computed tomography (CT) [20], intravascular 
ultrasound (IVUS) [21-23] and magnetic resonance imaging (MRI) [24-32].  Each 
method has its own merits; however, the focus of my research on MRI can be justified 
due to the lack of radiation exposure (compared to CT) and middle ground level of 
resolution (between IVUS and CT).  Our lab envisions MRI to be the best method of 
plaque imaging because it is noninvasive, gives a plethora of information relevant to 
plaques (e.g., morphology and inflammation) without the increased health concerns of 
radiation exposure. 
As developed with studies in both animals and humans, MRI is able to estimate the 
degree of luminal narrowing and differentiate between various plaque components [25-
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28].  With the addition of gadolinium-diethylenetriamine penta-acetic acid (Gd-DTPA), 
contrast enhanced MRI allowed an even more sensitive means of distinguishing plaque 
features, including the necrotic core [29], fibrous cap and the lipid core [33, 34].  Then, 
by using Gd-DTPA in conjunction with dynamic contrast enhanced (DCE) MRI, it was 
determined that neovascularization [35, 36] and inflammation [37], two characteristics 
linked with vulnerable plaques, both showed increased uptake of Gd-DTPA.  It has also 
been shown that MR at 3T is capable of detecting features of vulnerable plaques 
including outward remodeling, enhanced Gd-DTPA uptake, increased vessel wall size 
and increased plaque area in-vivo in a rabbit model of controlled atherothrombosis [24].  
These studies validated MRI as a viable method for evaluation of plaque vulnerability 
and falls in line with the goals of this dissertation. 
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1.4 The Rabbit Model of Atherosclerosis 
It is ideal to study atherosclerosis in humans, but there are numerous shortcomings that 
necessitate the use of animal models.  Specifically, the unpredictability of the time of 
plaque disruption (“spontaneity”) of plaque rupture and the urgency of care needed when 
ruptures occur in humans makes the study of ruptured plaques difficult.  Although post 
mortem studies can be done, and have provided a wealth of information on human 
atherosclerosis, it is clearly desirable and more important to study plaques pre-rupture 
and possibly even develop protocols to predict when these ruptures would occur.  To this 
end, the use of animal models can provide a means for studying controlled 
atherothrombosis, allows full control of experimental factors, and can even be used to 
study the efficacy of therapeutics.  With the wide array of animal models of 
atherosclerosis available, each with its own advantages, it was important to choose one 
that is ideal for the research proposed in Aims 1 and 2. 
The New Zealand White (NZW) rabbit model of atherosclerosis has been used 
extensively due to the ease of manipulation via diet modifications.  Groups have been 
able to produce both early lesion types [38-40] and advanced plaques [41-43] via dietary 
manipulation alone.  More importantly, rabbit models have been used to produce 
controlled plaque ruptures with thrombosis.    
Constantinides et al. used a combination of Russell’s viper venom (RVV), a 
procoagulant, and histamine, a vasopressor in rabbits that is mediated by an H1 receptor 
which regulates release of norepinephrine [44], in high fat fed rabbits to trigger plaque 
rupture and cause thrombosis with histological properties as thrombus found in humans 
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[42].  More recently, our lab has used a modified version of this high fat model with 
pharmacological trigger, with the addition of endothelial injury via balloon denudation 
(shown to accelerate plaque development [45-47]) to produce a rabbit model of 
accelerated controlled atherothrombosis. 
Abela et al. used the rabbit model of cholesterol feeding and balloon injury to explore a 
variety of atherosclerotic inducing protocols.  In this particular study, four groups of 
rabbits were subjected to different 8 month atherosclerotic protocols; normal diet, normal 
diet with balloon injury, cholesterol diet and cholesterol diet with balloon injury; all of 
which concluded with pharmacological plaque rupture triggering with RVV and 
histamine [47].  This study showed that thrombus formation was rarely found in models 
without the balloon injury (even with cholesterol feeding); however, cholesterol feeding 
without balloon injury still resulted in plaque formation.  In fact, the only group without 
plaque formation was the normal diet without balloon injury group [47].  This results 
shows that for this particular model, the balloon surgery (which causes endothelial 
dysfunction [48]) is necessary for the thrombosis event to occur after the triggering 
procedure.  
The particular model used in this study fed the rabbits a high cholesterol diet for 2 weeks 
prior to and 6 weeks after a balloon denudation surgery was performed.  The rabbits were 
then switched back to a normal diet for 4 weeks and pharmacologically triggered for 
plaque rupture with the RVV and histamine combination. An important benefit of our 
revised protocol   was a decrease in overall lipid toxicity to the rabbits, which may be due 
to the extended full month period on normal chow. Additionally, this protocol produced a 
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better range of plaques. Upon histological analysis, this model produced multiple 
histological plaque types found in humans and ruptured plaques had characteristics 
similar to those in humans.  These included inflammation; cholesterol esters in the intima 
and the fibrous cap; and thin fibrous caps [18]. 
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1.5 MRI of Atherosclerosis in Animal Models 
Magnetic Resonance Imaging (MRI) has been shown to be a valuable imaging modality 
of atherosclerotic lesions in both humans and animal models [24, 49-53].  It has been 
used to visualize and quantify changes in atherosclerotic plaques over time in both small 
(mouse [51, 54, 55]) and large (rabbits [56-58], pigs [59, 60]) animal models. Though 
used extensively to study atherosclerosis, mouse atherosclerotic plaques differ from 
human plaques, limiting their relevance to human disease [61, 62].  Even with these 
limitations, in vivo MRI of mice models has provided information on luminal narrowing, 
vascular remodeling [54], and other characteristics of atherosclerosis [51, 54, 55].  MRI 
studies in pig carotid arteries have provided information on disease states and 
vulnerability [60]. Studies of pig coronary arteries have shown features similar to those in 
our rabbit model in plaques that disrupt [63].  Although pig models have been reported to 
exhibit plaque rupture with distal embolism [64], there are no reports of controlled 
thrombosis with attached luminal thrombus in pigs.   
Because rabbit models can generate plaques that have luminal disruption as well as 
plaques that exhibit similarities to human coronary and carotid plaques [25], studies of 
rabbit models are potentially more translatable to the clinical setting.  An early study at 
1.5T on NZW rabbits fed a low (0.2%) cholesterol diet for an extended period (14-16 
months) with two balloon injuries in the abdominal aorta (at weeks 1 and 13 of the 
protocol) visualized changes in plaque features between 9 and 16 months [56].  In 
another study, NZW rabbits with cholesterol feeding (0.3%) for 4 months were imaged at 
4, 12, and 20 months later to compare progression and regression with continued feeding 
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of cholesterol or a return to normal chow at 4 months [50].  Ronald et al. found that NZW 
rabbits fed 0.3% cholesterol without balloon injury did not show significant outward 
remodeling even at 20 months [65].  In contrast, a Watanabe model using MRI, showed 
that aortic injury caused by balloon catheter produced plaques with compensatory 
outward remodeling [57].  However, these studies define vulnerability based on 
histological plaque characteristics, rather than plaque disruption [66].  
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1.6 Thrombosis 
As previously mentioned, plaques that disrupt causing thrombosis are of interest due to 
the complications resulting from such an event.  In fact, most acute clinical events have 
been documented to be caused by luminal thrombosis [14, 67-69].  Upon thrombosis, the 
eroding/rupturing of a plaque to form a luminal thrombus, the thrombi formed can either 
rapidly grow and cause sudden death, or can remain only partially occlusive and heal 
creating a larger plaque [70, 71].  More importantly, it was found that the majority of 
sudden deaths caused by plaque disruption, were caused by plaques that had previously 
healed, and then ruptured again [70].   
Of particular concern for this process is the fact that, at the site of thrombosis, the 
preexisting lesion frequently resulted in <50% stenosis [16, 17], making the current 
method of risk prediction used in the clinic unreliable.  In fact, only 20% of acute 
complete occlusions occur in lesions that result in >75% stenosis [72].  This leaves the 
other 80% of at-risk plaques virtually undetected, which motivates the study of these 
plaques at a high risk for disruption via other, possibly more accurate methodologies. 
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1.7 MRI Scans 
The scans used for imaging of atherosclerosis include T1 weighted black blood (T1BB), 
T1 weighted black blood with fat suppression (T1BB-FS), contrast enhanced T1BB-FS 
(CE T1BB-FS), dynamic contrast enhancement (DCE) and 3D quantitative flow (3D Q-
Flow). 
The T1BB scan with cardiac gating was used to null the signal from flowing blood and 
minimize motion artifacts from heart rhythm.  This provides images with blood in black 
and allows the visualization of the vessel wall.  However, when analyzing these images, 
the vessel wall area may be pooled with the anatomically joined periotic fat, thus giving a 
false (larger) vessel wall area report.  In order to minimize this error, a T1BB-FS 
sequence was used.   
The T1BB-FS sequence exploited the relaxation rate differences between fat and water in 
order to suppress fat signals.  The specific protocol used was a spectral inversion 
recovery (SPIR) pulse sequence.  SPIR uses the fact that fat has a very short T1.  First a 
preparation pulse is fired, and after a short delay (longer than the T1 time of fat), the data 
acquisition begins.  This allows for the fat T1 signal to completely fade before acquiring 
data for the surrounding tissue (all with longer T1 times and therefore still providing a 
signal).  Additionally, the SPIR protocol selectively flips fat magnetization only, it is also 
suitable for post contrast enhanced (gadolinium) imaging as well.   
The CE T1BB-FS is just the T1BB-FS scan after the injection of the contrast agent, 
gadolinium.  This scan uses the addition of gadolinium (a paramagnetic atom approved 
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by the Food and Drug Administration, FDA, for clinical use), which shortens the T1 
relaxation time of surrounding tissues.  This causes tissues that trap gadolinium to 
become hyper bright in T1 weighted MRI’s.   
The DCE scan consists of a series of T1 weighted scans.  First a baseline scan is 
performed, then after the contrast agent is administered, a series of scans are performed in 
a short amount of time (over 2-5 minutes) to generate images of gadolinium uptake as 
time progresses.  By analyzing each image at all time points, the rate of contrast uptake 
can be calculated.   
The scans listed here can be found in the MRI computer at Boston University’s Center 
for Biomedical Imaging (CBI) center.  The scan card used in our studies can be found 
under BU Users à Hamilton à Serial Rabbits. 
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1.8 MR Derived Characteristics and Vulnerability 
Although many groups have been able to identify features associated with vulnerable 
plaques, as determined by histology, using MRI [27, 29, 33, 34, 49], CT [73] and IVUS 
[21-23, 74]; there are few studies that have prospectively predicted which plaques are 
likely to rupture and cause a cardiovascular event [24]. 
Using MRI, many groups have been able to reveal certain plaque or vessel characteristics 
that are associated with atherosclerotic plaque vulnerability.  The scans used for this 
thesis work reveal characteristics of plaques including the outer vessel area, the lumen 
area, and signal intensity increases (with the help of a contrast agent).  From these 
parameters, various calculations can be made to determine features associated with 
plaque vulnerability such as the remodeling ratio (RR) and the percent increase in 
gadolinium uptake. 
The RR is a geometric description value that describes how much larger a specific 
portion of the vessel is compared to how large it should be (compared with the rest of the 
vessel).  From both histological and in vivo imaging studies, this remodeling process has 
been recognized as a mechanism that alleviates luminal narrowing.  Additionally, studies 
have shown that this compensatory process is related to plaque vulnerability in IVUS [74, 
75], MRI [24] and CT [73] imaging modalities among others.  Since this parameter is 
relatively easy to calculate and has even been used to create vulnerability cut-off values 
[75, 76], it can be a powerful tool in assessing plaque vulnerability.     
	  	  
19 
Gadolinium uptake into the plaque has been associated with plaque neovascularization, 
inflammation, endothelial permeability, and fibrosis in both human [29, 35, 36, 77] and 
animal models [36].  Moreover, its association with vulnerable plaques has been 
explored, making it another valuable minimally invasive method for determining plaque 
vulnerability [24, 78]. Although other formulations with gadolinium have been designed 
and have benefits for detecting advanced and vulnerable plaques, including specific 
components such as fibrin [79] , we have shown that Gd-DTPA (Magnevist) is sufficient 
when used in combination with our other measures of plaque vulnerability to discriminate 
high risk plaques. 
The parameters presented here are just two of the many plaque characteristics that can be 
extracted from the use of MRI.  Although these two predictors of plaque ruptures alone 
do not produce a viable predictive power for clinical use, a combination of the two could 
prove to have the sensitivity and specificity needed in the clinic [24].  Additionally, with 
the myriad of other characteristics and imaging modalities, it is hard to believe that there 
would be no combination of parameters that would yield sufficient predictive power 
while minimizing time and cost inputs. 
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1.9 Pro-resolution Molecules  
Pro-resolution molecules are substances that promote the resolution of inflammatory 
processes.  Of particular interest and importance are resolvins and lipoxins.  Both 
substances are found endogenously in the body.  The resolvins are derived from the ω-3 
fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and the 
lipoxins are derived from the ω-6 fatty acid, arachidonic acid.  Although the exact 
mechanism of their pro-resolution of inflammation has not been elucidated, there is much 
evidence that they are indeed involved in the process. 
Resolvins are classified in two major categories, the E series (derived from EPA) and the 
D series (derived from DHA).  Figure 1 shows the derivation of an E series resolvin from 
EPA.  In this particular example, the cyclooxygenase enzyme COX-2 introduces an 18R 
hydroperoxy group into the EPA.  Then it is reduced into a hydroxyl compound before a 
5S-hydroperoxy group is added to the molecule by the enzyme 5-lipoxygenase.  At this 
point, the molecule could be reduced into resolvin E2 or it can be converted into a 5, 6-
epoxy fatty acid and further into resolvin E1.  Resolvins have been shown to regulate 
neutrophils [80] and reduce skin inflammation [81] and have anti-inflammatory 
properties [82]. 
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Figure 1:  The creation of Resolvin E1 from EPA.  This reaction was taken from 
Christie [83].   
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Lipoxygenase interaction products (Lipoxins), are eicosanoids produced endogenously 
that have anti-inflammatory properties [84].  Figure 2 shows one of the reaction pathways 
that occur in the creation of lipoxins (both A4 and B4 variants) from arachidonic acid.  
The arachidonic acid metabolite 15S-hydroperoxy-5c,8c,11c,13t-eicosatetraenoic acid 
(15S-HPETE) is acted on by 5-lipoxygenase to form first an epoxy intermediate: 5S,6S-
epoxy-15S-hydroxy-ETE.  This is then hydrolyzed to form either the lipoxin A4 or B4 
variants [85].       
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Figure 2:  The creation of Lipoxins from arachidonic acid metabolite (15S-HPETE).  
This reaction was taken from Christie [85]. 
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Of particular interest to this thesis work is the lipoxin A4 (LXA4) variant, one of two 
principle forms of lipoxin formed in mammalian cells.  Although the exact mechanism 
involved with resolution of inflammation via LXA4 has yet to be elucidated, there is 
much evidence in its involvement in the anti-inflammation cascade. 
Discovered by Serhan et al. [86], lipoxins have been implicated as inhibitory signals in 
the inflammatory process [84, 87].  Lipoxins have been found to be involved with the 
stimulation of monocytes and macrophages, as well as the inhibition of 
polymorphonuclear neutrophils, eosinophils and lymphocytes [84, 87, 88].  It is thought 
to be one of the key regulators of acute inflammation resolution which leads to recovery 
of damaged tissue after an effective host defense event [89].  During inflammatory 
diseases such as chronic asthma [90], liver disease [91] and leukemia [92]; lipoxin 
generation is diminished; thus indicating the pro-resolution properties of the lipoxin. 
These properties, make lipoxins a choice for the resolution of atherosclerosis, a chronic 
inflammatory disease. 
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1.10 Intravascular Ultrasound in Plaque Imaging 
Although intravascular ultrasound (IVUS) readily detects the vessel wall and in luminal 
narrowing, it provides limited information about plaques, such as whether they are lipid-
rich or calcium rich.  Nevertheless, in spite of its invasive nature, efforts are underway to 
develop targeted contrast agents in order to improve the functionality of US. Studies 
using IVUS on plaques that lead to acute coronary syndrome have shown that these 
plaques were generally eccentric, relatively free of calcification, was positively 
remodeled and hypoechoic [93].  Although these descriptors of unstable plaques seem 
reasonable, there are a number of reasons that IVUS is not currently an accepted modality 
to locate and characterize vulnerable plaques.  These include the low resolution of IVUS 
(150-300 um), the fact that stable plaques have been found to share some of the same 
characteristics as vulnerable plaques via IVUS and the fact that nearly all of the IVUS 
experiments have been performed after an acute event.  After an event, the plaque 
characteristics could change and this approach does not provide morphology data of the 
plaques prior to the incident.  These limitations led to the development of many IVUS 
imaging techniques including 3D IVUS with integrated back scatter, wavelet analysis of 
RF IVUS and the development of US contrast agents, particularly in the form of micro-
bubbles, to be used with various US protocols [94]. 
  
	  	  
26 
1.11 Microbubbles as a Contrast Agent and Drug Delivery Vehicle 
Microbubbles have many medical applications, including targeted drug and gene delivery 
vehicles, clot destruction, ultrasound contrast agents (UCAs) and targeted UCAs [95].  
Previously, it has been shown that with the addition of UCAs the visualization of blood 
vessels via ultra sound (US) is possible [96].  To further enhance the signal correlation 
during US imaging, monodisperse lipid encapsulated microbubbles were used [97].  
Following this advancement, the development of targeted UCAs yielded selective 
microbubbles for site specific US contrast enhancement for markers of thrombosis [98], 
inflammation [99, 100] and much more.  UCAs have also been studied as therapeutic 
agents for targeted drug [101-109] and gene delivery [101, 110, 111] systems. 
It has been shown that by trapping an effective cytotoxic drug in a liposome, highly 
adverse systemic effects the drug can be minimized [112, 113].  This is ideal for 
delivering anti-angiogenesis drugs and anticancer drugs such as Paclitaxel or 
Doxorubicin, which both have adverse systemic effects.  Generally, especially for cancer 
or inflammatory based diseases, it would be ideal for these drugs to be targeted to the 
region of disease in order to minimize systemic effects and maximize therapeutic results.  
Hence, targeted US microbubble contrast agents are well suited for local drug delivery.  
Using targeted UCAs, one could load the desired drug into the microbubble, inject it 
either locally or systemically into the body, allow it to find and attach to its target and 
then use ultrasound to disrupt the microbubbles, releasing the drugs [114, 115].  
Unfortunately, microbubbles do not allow for sufficient volumes of drugs to be delivered 
when the drugs are simply allowed to incorporate into the lipid head groups.  There has 
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been much research on increasing the microbubble payload via mounting drug loaded 
liposomes onto the microbubble surface [104] as well as utilizing a multilayer liposphere 
[116] as shown in Figure 3.  As depicted, the multilayered microbubble with an 
acoustically active gas core allows for a hydrophobic drug to be dissolved into the oil 
layer, thus increasing the drug payload. 
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Figure 3:  Generic Targeted Microbubble with Oil + Drug Layer for Added Drug 
Payload.  Adapted from Hettiarachchi et al. [116]. 
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1.12 Microbubble Fabrication Methods 
Currently, the two prevalent methods of microbubble fabrication are emulsification via 
tip sonication [117] and via flow-focusing [118-121].  Due to the acoustic advantages that 
monodisperse bubbles provide over a polydisperse population, our efforts will be on 
flow-focusing methods [97].  The creation of monodisperse microbubble populations has 
been generated successfully using flow-focusing [118, 122].  Flow-focusing microbubble 
creation can be accomplished by both single and double emulsion techniques.  The single 
emulsion microfluidic devices allow for the fabrication of a lipid monolayer 
encapsulating a gas core, while a double emulsion device would allow a gas core 
surrounded by an oil layer, which is in turn surrounded by a lipid monolayer as shown in 
Figure 3.  Additionally, these devices provide tenability in bubble sizes by varying the 
viscosities of the entering fluids [123], as well as the fluids’ flow ratios [124].   
Both types of microfluidic devices are made using a soft photolithography technique 
[125] to create an SU-8 reverse mold of the device on a thin silicon wafer, then using 
silicone elastomer polydimethylsiloxane (PDMS) to cast a stamp of the pattern from the 
wafer.  Once the stamp is made, holes are punched where necessary and the device is 
bound to a glass slide via plasma ashing.  Since there are some problems in microbubble 
fabrication (device clogging, etc.), this method provides for easy access to new 
microfluidic devices without complicated processing or fabrication. 
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1.13 Polymerizable Lipids 
Microbubble UCAs provides a valuable tool for US diagnostics, but have some flaws that 
need to be addressed.  Currently, UCAs are unable to provide sufficient acoustic signals 
in vivo [126] and have poor blood circulation times due to instability.  To improve both 
of these properties, the shell composition of the UCAs can be altered to improve 
bloodstream stability [127] and change the surface elasticity [128, 129] and surface 
tension [130], thus affecting echogenicity.  The addition of poly(ethylene glycol) (PEG) 
onto the lipids provide further stability, preventing aggregation [131] and binding of 
plasma proteins [132, 133].  The use of Di-acetylene lipids allow for polymerization 
under UV exposure at 254nm and have been shown to prevent drug leakage in liposomes 
for an extended period of time in physiological conditions [134], thus allowing for a more 
controlled drug delivery vehicle. 
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 Chapter 2:  Serial MRI to Track the Progression of Atherosclerosis 
 
This chapter focuses on Aim 1 of my thesis work.  The goal of this work was to identify 
MRI derived plaque features that are associated with plaque rupture risk as early as 
possible in the atherosclerotic protocol presented in the animal model used.  This work 
serves to provide evidence for the feasibility of using MRI derived features as predictive 
parameters when evaluating a plaque’s risk of rupturing and causing a cardiovascular 
event. 
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2.1 Significance 
Atherosclerotic plaque rupture or erosion and subsequent luminal/mural thrombus 
formation [66] may lead to myocardial infarction and stroke [4, 5], which are among the 
leading causes of death in the United States [6].  The ability to noninvasively monitor 
changes in atherosclerotic lesion features in vivo could provide insights into the 
development of plaque vulnerability and identification of plaques that are at high-risk for 
thrombosis [135].  Studies of the natural evolution of plaques in humans have many 
limitations, including the long duration of plaque progression and the inability to induce 
disruption as an endpoint for determining the high-risk plaques or to follow a specific 
plaque from an early stage to its disruption. Thus, studies of animal models with 
validated histology and in vivo characteristics that replicate human disease are invaluable 
for providing insights into human plaque progression and regression.   
In Chapter 1, I have commented on the benefits of using MRI to distinguish features of 
plaques in vivo as well as the pros and cons of various animal models of atherosclerosis.  
This chapter will be focused on Aim 1: Establishing hallmarks of plaque vulnerability 
in an animal model.   
The novelty of the work presented here is the application of MRI to monitor the natural 
history of vulnerable plaques in a modified Constantinides rabbit model [47, 136] of 
atherothrombosis with the functional endpoint of plaque disruption.  The lab has 
previously optimized the atherosclerotic preparation protocol to produce complex lesions 
that encompass 6 of the 8 AHA established human plaque classifications [8, 18].  
Additionally, histological studies of this particular model showed increased vessel wall 
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area, excessive outward remodeling, inflamed fibrous cap, adventitial breakdown and 
neovascularization were highly associated with plaques that disrupted [18].  Another 
previous study used MRI of the rabbit aorta prior to pharmacological triggering to 
noninvasively measure vessel wall area, outward remodeling and gadolinium uptake [24], 
which reflects a combination of inflammation, neovascularization and vessel wall 
degradation.  Here, serial MRI was applied to monitor individual plaques in a rabbit aorta 
over a 3-month period with the goal of evaluating whether or not these MRI 
measurements made previously only at 3 months reveal differences earlier in the 
development and differentiation of the individual plaque segments.   
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2.2 Methods:  Rabbit Model of Atherosclerosis 
The rabbit model used was prepared using a protocol previously established in the 
Hamilton lab by Alkystis Phinikaridou [18, 24].  The model was modified from the 
original Constantinides rabbit model of atherothrombosis and has been shown to produce 
advanced plaque lesions as well as plaque ruptures leading to thrombosis.  
Male New Zealand White (NZW) rabbits (n=12, Rabbits 01-12) were purchased from a 
local rabbit farm (Pine Acres, Norton, MA) at 3 months old with weights ranging 
between 2.5kg and 2.8kg.  Upon arrival to the Boston University Laboratory Animal 
Science Center (BU-LASC), the rabbits are given a week to acclimate to their new 
surroundings as required by protocol.  To produce the required atherosclerotic plaque 
regions needed for the study, the animals were fed a 1% cholesterol diet (PharmaServe, 
Framingham, MA) for a total of 8 weeks with minimal intake of other foods such as hay 
and fruits/vegetables (these were only given as directed by the veterinarian staff to ensure 
animal health).  Two weeks into the high cholesterol diet (HCD), a balloon catheter 
surgery was performed to cause endothelial damage and accelerate the atherosclerotic 
process.   
The surgery was performed by an animal surgeon under general anesthesia in accordance 
to the Institutional Animal Care and Use Committee (IACUC) approved protocol.  The 
animals were injected with acepromazine (0.75 mg/kg, IM) followed 5-10 minutes later 
with an injection of ketamine (35 mg/kg, IM) and xylazine (2.5 mg/kg, IM).  Once 
completely anesthetized, the rabbit was placed in the supine position and the right inner 
thigh was shaved and triple washed (Betadine and ethanol) to expose and sanitize the 
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surgery site.  A small incision was made above the right femoral artery (right inner thigh) 
and a 3F Fogarty catheter was inserted into the right femoral artery via an aortic cutdown.  
The catheter was then threaded through the aorta and to the diaphragm.  Once in position, 
the balloon was inflated (via a 1ml syringe) and the catheter was gently withdrawn back 
towards the insertion site.  This insertion and withdrawal process was completed 3 times 
per animal and caused endothelial cell detachment along the vessel wall.  The injury site 
covered the entire abdominal aorta, including our region of interest, which spans from the 
iliac bifurcation to the left renal bifurcation.  The surgery process is summarized in 
Figure 4.      
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Figure 4:  3F Fogarty is inserted into the right iliac artery cutdown and threaded to 
just above the left renal bifurcation.  The balloon is then inflated and entry 
extracted from the left renal to the iliac bifurcation.  This process is repeated 3 times 
to cause endothelial damage.  It is important to note that the endothelial cells 
regenerate overtime after injury and that this injury is not a permanent removal of 
endothelial cells [18].  
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After this surgery, the rabbits continued their HCD for an additional 6 weeks, completing 
the 8-week HCD period.  Then, the rabbits were fed normal rabbit chow for an additional 
4 weeks which has been shown to reduce lipid toxicity and allowed the atherosclerotic 
lesions to further develop.  The timeline is shown in Figure 5. 
Magnetic Resonance Imaging and Plaque Rupture 
During the atherosclerosis development protocol, the animals were imaged serially via 
MRI at the 0 month (baseline, immediately after acclimation and before any experimental 
manipulations), 1 month, 2 month and 3 month time points to track the progression of the 
disease (Figure 5).  All MR scans were performed under general anesthesia as previously 
described for the balloon surgery (acepromizine, ketamine and xylazine), which provided 
about an hour of scan time.  If more time was required, an additional booster dose (half 
the amount of the original dose) of the anesthesia drugs was administered.  The animals 
were imaged in a 3T Phillips Intera Scanner (Philips Medical Systems, Ohio).  Once 
anesthetized, the rabbits were placed in the supine position in a synergy 6 element knee 
coil, placed into the magnet and scanned.  Multiple MR scans were completed on each 
rabbit at each time period in order to maximize the amount of data we obtained from 
these animals.   
First, a survey scan was performed in order to obtain low quality macroscopic images of 
the entire animal in the sagittal, axial and coronal planes.  This allowed visualization of 
the animal and provided the location of the abdominal aorta.  Once found, the aorta is 
scanned on the sagittal and coronal planes with a slightly higher resolution in order to 
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position the data collecting scans:  T1 weighted black blood (T1BB), T1 weighted black 
blood with fat suppression (T1BB-FS), dynamic contrast enhancement (DCE), and 
contrast enhanced T1BB-FS (CE T1BB-FS).   
An additional CE T1BB-FS scan was performed 48 hours after the 3-month scan (after 
pharmacological triggering for plaque rupture) to determine the location of mural thrombi 
within the animal’s vessel.  The plaque triggering portion of the experiment was 
performed immediately after the 3 month scan and consisted of an intraperitoneal 
injection (0.15 mg/kg) of Russell’s Viper Venom (RVV; Enzyme Research, South Bend, 
IN) followed 20-30 minutes later by an IV injection (0.02 mg/kg) of histamine (Sigma-
Aldrich, St. Louis, MO).  The combination of the vasopressor (histamine), the 
procoagulant factor (RVV) and the endothelial toxin (RVV) [137] create an ideal 
environment for vulnerable plaque ruptures and thrombi formation.  The rabbits are 
triggered in the same manner again 24 hours after the first triggering process.  Finally, 24 
hours after the second triggering, the rabbits are scanned again, but the final scan only 
consists of the CE T1BB-FS scan sequence for thrombi detection, taking a total of 20 
minutes for the scan (not including preparation time). 
The experiments performed here were all in accordance to the approved IACUC protocol; 
however, even with such precautions, one rabbit did not survive the study due to 
suspected multi-organ dysfunction.  This resulted in a final experimental group size of 11 
animals.  The entire scan protocol is summarized in Figure 5. 
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Figure 5:  Experimental protocol timeline.  After acclimation period, the animals 
are scanned immediately prior to manipulation to obtain baseline images.  They are 
then placed on a HFD for 2 weeks, given the balloon surgery, placed back on the 
HFD for an additional 6 weeks and finally put on a normal diet for 4 weeks.  During 
this time, they are imaged at the 1, 2 and 3-month time points, with an additional 
scan post plaque rupture triggering 48 hours after the 3-month scan.  
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Image Analysis 
Images obtained via the T1BB-FS and the CE T1BB-FS scans were analyzed by 
performing manual segmentation using ImageJ (National Institute of Health, NIH).  For 
the T1BB-FS images, a region of interest (ROI) was drawn around the adventitial and 
luminal contours of the vessel wall as depicted in Figure 6.  Fat suppression was added to 
this protocol in order to more accurately elucidate the vessel wall via suppression of 
adventitial fat surrounding the vessel wall.  This process is explained in detail in Chapter 
1. 
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Figure 6:  Image analysis procedure for both T1BB-FS and CE T1BB-FS image sets.  
The left image (coronal) in A shows the entire abdominal aorta for the rabbit.  Axial 
images are taken every 4mm within the aorta to produce the image shown in B.  
Analysis is performed by zooming in (red box in B) and manually segmenting the 
outer vessel wall area and lumen area as shown in A for two different sections of the 
aorta. 
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The lumen area (LA) ROI was drawn to encircle the black blood signal (Figure 6B) while 
the outer vessel wall area (OVWA) ROI was drawn to encircle the adventitial area 
(Figure 6C).  Similarly, the CE T1BB-FS images were analyzed the same way, but the 
images were normalized using the external standard (to normalize pixel intensities across 
images).  From these two data sets, information on the LA, OVWA, vessel wall area 
(VWA), remodeling ratio (RR) and gadolinium contrast enhancement (Gd-CE). 
The LA and OVWA were calculated by using the values outputted by ImageJ from the 
corresponding ROI for each parameter.  The VWA was then obtained by subtracting the 
lumen area from the outer vessel wall area using Equation 2.1. 
VWA =   OVWA− LA 
Equation 2.1:  Vessel wall area calculation.  Where VWA = vessel wall area, OVWA 
= outer vessel wall area and LA = lumen area. 
Previously, the lab used this value as a plaque area; however, a renaming of this 
parameter was decided upon because using MRI, it is difficult to differentiate the actual 
VWA from the plaque itself.  Therefore, the VWA, as calculated here, includes both the 
vessel wall and plaque areas which we consider a valid method of comparing plaques 
because atherosclerosis is a disease that effects the entire vessel wall in a systemically as 
shown in our histology (Chapter 3). 
To calculate the RR some preliminary data adjustments had to be performed first.  The 
abdominal aorta of a rabbit has a natural taper to it, being smaller at the iliac bifurcation 
and increasing in size toward the left renal bifurcation.  Since the RR is a measure of how 
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much larger a vessel segment is compared to the rest of the segment, this tapering had to 
be corrected to simplify this comparison.  This was done by plotting the OVWA values 
vs. the segment’s distance from the iliac bifurcation.  Then, a slope of the best-fit trend 
line was calculated.  Each segment’s outer vessel wall area was then corrected by 
Equation 2.2. 
COVWA = OVWA− S×D 
Equation 2.2:  Corrected outer vessel wall area calculation.  Where COVWA = 
corrected outer vessel wall area, OVWA = outer vessel wall area, S = slope of trend 
line and D = distance of that segment from the iliac bifurcation.   
An example of both the original (blue) and corrected (orange) outer vessel wall areas 
from one rabbit is shown in Figure 7.  Note that corrected data’s trend line has no slope 
(or a very small one), indicating that there is no overall tapering. 
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Figure 7:  Example outer vessel wall area correction data.  The process detailed here 
uses the slope from the OVWA data and Equation 2.2 in order to correct for aortic 
tapering.  The left side shows a pictorial representation of this process.  
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Once corrected, the RR was calculated by taking the OVWA of each segment and 
dividing it to serve as the OVWA of a reference segment.  This reference segment is 
chosen for each rabbit as the segment with the smallest VWA, which is chosen to signify 
the segment of the aorta that was least effected by atherosclerosis.  This division 
compares how large an aortic segment is compared to a segment that is presumably the 
healthiest segment in the rabbit.  Equation 2.3 shows the calculation process for the RR. 
RR = OVWA!"#OVWA!"# 
Equation 2.3:  RR calculation.  Where RR = remodeling ration, OVWASeg = outer 
vessel wall area of a segment and OVWARef = outer vessel wall area of the reference 
segment. 
RR’s were categorized conventionally as follows: RR > 1.05 (positive remodeling), 
0.95<RR<1.05 (intermediate remodeling) and RR<0.95 (negative remodeling) [138].   
Gd-CE was calculated using the CE T1BB-FS images.  First, the images’ pixel intensities 
were normalized to the external standard (same concentration of Gd throughout the 
study) and then the ROIs were drawn to again encompass the lumen and outer vessel wall 
areas.  Once these areas were obtained, the average vessel wall contrast enhancement 
(Gd-CE) was determined via Equation 2.4. 
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Gd− CE = OVWA×OVWAI − [LA×LAI]VWA  
Equation 2.4:  Vessel wall contrast enhancement.  Where Gd-CE = the gd 
enhancement of the vessel wall area, OVWA = outer vessel wall area, OVWAI = 
total pixel intensities of the outer vessel wall area ROI, LA = lumen area, LAI = 
total pixel intensities of the lumen area ROI and VWA = vessel wall area.  
This calculation provided the average pixel intensity of pixels within the VWA.  To make 
this a measured quantity over time, each segments Gd-CE was normalized by the Gd-CE 
of itself at the 0 month (baseline) time point.  Then a percentage of Gd-CE increase was 
calculated using Equation 2.5.  
%Gd− CE = [ Gd− CE!"#Gd− CE!"#$%&'$×100]− 1 
Equation 2.5:  Calculation of percent increase in contrast enhancement.  Where 
%Gd-CE = percent increase of contrast enhancement from baseline, Gd-CEseg = 
pixel intensity of segment, Gd-CEbaseline = pixel intensity of same segment at baseline 
time point. 
Up to this point, the total scan time ranged between 45-60 minutes, depending on various 
factors.  The length of time and anesthesia methods stressed the rabbits to some extent 
and the addition of the remaining scans (4D Q-Flow, 3D Q-Flow and DCE) add another 
hour or so to the protocol, further stressing the animals.  For the remaining scans (4D Q-
Flow, 3D Q-Flow and DCE), image analysis programs were going to be obtained from 
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various collaborating groups.  However, this never came to fruition, so the data was not 
analyzed.  Originally, these scans were to provide flow visualization (4D Q-Flow), 
quantitative flow rates for endothelial shear stress analysis (3D Q-Flow) and initial 
dynamic gd uptake rate (DCE) information. 
Image Matching and Segment Classification 
For each rabbit, images were obtained every 4mm starting from the iliac bifurcation and 
ending just above the left renal bifurcation.  To track aortic segments over time (between 
scans), an alignment system was adapted.  Starting from the baseline scan, segments were 
identified by their distance from the iliac bifurcation.  That is, an MRI image of a 
segment that was 40mm from the iliac bifurcation in the 1-month scan was considered to 
be the same segment that was 40mm from the iliac bifurcation in the baseline scan 
(Figure 8).  Figure 9A shows the magnetic resonance angiography (MRA) coronal image 
of the abdominal aorta used for a segment that had a luminal thrombus post-trigger (as 
indicated by Figure 9B and C).  Again, using the distance from the iliac bifurcation as an 
anatomical marker, the segment was identified physically (Figure 9D), imaged via Ex 
vivo MRI (Figure 9E) to help guide histology (Figure 9F).  This was the convention for 
all scan time points.   
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Figure 8:  Image alignment from time point to time point.  Images of aortic 
segments were aligned and compared using their distance from the iliac bifurcation 
as a marker.   
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Figure 9:  Histology and image matching diagram.  A) MRA image of the abdominal 
aorta.  B + C) Images of an aortic segment before and after plaque rupture 
triggering.  The existence of a thrombus is seen, deeming this segment as disrupted.  
D) Measuring the physical aorta from the iliac bifurcation to determine the location 
of the aortic segment imaged (yellow dotted box in A matches to black dotted box in 
D).  E1-E4) Ex vivo MRI images of the aortic segment used to guide sectioning.  F1-
F4) Corresponding stained histological slices of the aortic segments shown in E1-E4.  
Figure is adapted from Phinikaridou et al.  [18]. 
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For the comparisons of aortic segments, each image was classified as either a disrupted or 
a non-disrupted segment.  This was done by viewing the post triggered MRI images (the 
scan performed 48 hours after the 3 month scan).  In these images, if a luminal thrombus 
was present, then that segment was considered a disrupted segment and if there was no 
thrombus, then it was classified as a non-disrupted segment.  When a specific segment 
was classified as disrupted, then that segment was considered predisposed to disruption 
and was classified as such at all time points of the experiment.  An example of what a 
typical thrombus looks like in a post triggered MR image is shown Figure 10. 
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Figure 10:  Post triggered MR images of the rabbit aorta.  The non-disrupted aortic 
segment has a lumen free of thrombus, while the disrupted segment exhibits an 
attached thrombus (green arrow). 
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Histology  
After the final imaging session, the animals were euthanized with Beauthanasia D 
(0.5ml/kg, IV) and the abdominal aorta was extracted from just below the iliac 
bifurcation to right above the left renal bifurcation.  The aorta was then stretched out to 
the in vivo length (measure prior to excision) and pinned down onto a tissue pan.  Then, 
it was fixed with a 10% formalin solution (Thermo Scientific, Waltham, MA) to prevent 
further degradation of the sample.  Upon unpinning the samples, there is still some 
shrinkage, but this is generally negligible.  
This particular set of rabbits was also used for a separate experiment (non-thesis related) 
that required the aortas to be cut open longitudinally, rather than the usual procedure of 
cutting the aorta into 2cm segments for ex-vivo MRI, from which axial slices are cut for 
histology.  This caused histological slices cut from the opened aortas to unsuitable for 
MRI comparison.  However, previous extensive studies done in the lab has adequately 
demonstrated the relationship between the histology and the MR images [18, 24].  The 
samples were cryosectioned transversely (10 µm slices) throughout the length of each 
sample.  The samples were also stained for cellular components (collagen, connective 
tissue, etc.) and thrombi using Masson trichrome (Sigma Aldrich).  This allows the color 
coded visualization of the foamy macrophages, lipid core, necrotic core and fibrous cap.    
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Statistical Analysis 
All statistical analysis was performed using Excel (Microsoft, Redmond WA).  For 
comparisons between disrupted and non-disrupted plaques, a 2-sample t-test was used 
with a statistical significance threshold of p<0.05.  Data are presented as mean ± standard 
error in figures, tables and text.  
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2.3 Results 
Serial MRI Can Discern Characteristics of At-risk and Stable Plaques Over Time 
Of the 12 rabbits used for this study, one died due to suspected multi-organ failure.  
Atherosclerotic plaques were observed in a total of 11 rabbits by MRI, 10 of which 
developed thrombus at the end point of the study.  Within these rabbits, a total of 181 
aortic segments were analyzed, 39 (21.5%) of which were classified as disrupted.   
Figure 11A shows an exemplary example of serial images obtained for a disrupted and a 
non-disrupted plaque within the same rabbit. A qualitative assessment of the VWA and 
signal enhancement showed that the both plaques were similar at baseline and 1 month.  
At 2 months, the two types of plaques became different with respect to the RR and 
contrast enhancement.  The non-disrupted plaque showed a small increase in RR and 
signal enhancement, while the disrupted plaque showed a significant increase in RR and 
signal enhancement. As the disease progressed, the disrupted plaque showed an even 
more pronounced increase in RR and Gd-CE as compared with the non-disrupted plaque.  
The quantitative changes for these two specific plaques are plotted in Figure 11B and C.     
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Figure 11:  Exemplary example of a disrupted and a non-disrupted aortic segment 
from the same animal.  A) Time course T1BB-FS and CE T1BB-FS images for both 
a disrupted and a non-disrupted segment.  B) RR measurements for images shown 
in A.  C) Increase from baseline of the average signal intensity of the vessel wall for 
the images in A.   
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Figure 12: Additional example of a disrupted and a non-disrupted aortic segment.  
A) Time course T1BB-FS and CE T1BB-FS images for both a disrupted and a non-
disrupted segment.  B) RR measurements for images shown in A.  C) Increase from 
baseline of the average signal intensity of the vessel wall for the images in A.  This 
example shows that the non-disrupted segment had a similar signal intensity profile 
as the disrupted segment (C), which is different from the previous example.   
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Figure 12 shows another example of serial images of a disrupted and a non-disrupted 
plaque.  In this particular example, the RR for the disrupted plaque increases over time 
and the non-disrupted segments RR remains relatively stable (Figure 12B).  When 
viewing the signal intensity increase over time, both segment types show a similar trend 
(Figure 12C), which is contrary to the previous example in Figure 11.  Figure 12A also 
shows a qualitative difference between this particular disrupted plaque (less signal 
enhancement and not as dramatic an increase in RR) and the disrupted plaque shown in 
Figure 11.  
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MRI Can Reliably Detect Features of Plaque Vulnerability at 2 Months 
The previous images show two examples of a comparison of stable vessel region and a 
vulnerable region over time. This demonstrates the feasibility of imaging changes in 
plaque progression in a patient on a plaque-by-plaque basis. However, it does not address 
the overall reliability of the MRI measurements.    
To assess the reliability of the MRI features illustrated for the two rabbits above, we 
averaged data over all 181 aortic segments for both non-disrupted and disrupted plaques.  
The VWA of the non-disrupted plaques and disrupted plaques both showed a trend of 
decreasing in size from baseline to 1 month.  This occurred between the initiation of 
cholesterol feeding and balloon injury at 2 weeks.  However, at 2 months, the VWA of 
the disrupted segments remained the same as it did at 1 month, while the non-disrupted 
segments exhibited a continued decrease in VWA size.  This difference between the 
stable and vulnerable regions was enough to create statistical significance for VWA 
between the two groups (6.30±0.11mm2 vs. 6.99±0.25mm2; p=0.0072) at 2 months.  This 
difference was even more pronounced moving to 3 months, with the non-disrupted 
segments increasing in VWA size, but only slightly compared to the size increase shown 
by the disrupted segments (6.81±0.13 mm2 vs. 8.19±0.43 mm2; p=0.0001).  Figure 13 
shows these data in graphical form. 
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Figure 13:  VWA trend over time.  The disrupted plaques had a statistically larger 
VWA compared to non-disrupted plaques at 2 and 3 months (6.30±0.11 mm2 vs. 
6.99±0.25 mm2 and 6.81±0.13 mm2 vs. 8.19±0.43 mm2, respectively).  The (*) and 
(**) refer to statistical significance (p=0.0072 and p=0.0001, respectively) as indicted 
by a 2-tailed t-test. 
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For the RR of the segments, the non-disrupted segments decreased from baseline to 1 
month and further to 2 month. Then, it increased a little at 3 month.  The disrupted aortic 
segments actually increased from baseline to 1 month to 2 month, with a slight decrease 
in value at 3 month.  The two segment types exhibited inverse trends and were 
statistically different at both the 2 and 3-month time points.  The disrupted segments had 
a larger RR at 2 month (1.05±0.02 vs. 0.97±0.01; p=0.0002) and 3 month (1.04±0.02 vs. 
0.99±0.01; p=0.0209), with the 2-month time point showing the largest difference 
between the two groups.  Figure 14 shows the RR of both groups at the corresponding 
time points. 
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Figure 14:  RR trend over time.  The disrupted plaques had a statistically larger RR 
compared to non-disrupted plaques at 2 and 3 months (1.05±0.02 vs. 0.97±0.01 and 
1.04±0.02 vs. 0.99±0.01, respectively).  The (*) and (**) refer to statistical 
significance (p=0.0002 and p=0.0209, respectively) as indicted by a 2-tailed t-test. 
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To provide additional insight into the RR changes, we compared the percentage of 
segments that had an RR of 1 and under, between 1 and 1.05 and above 1.05, which 
represents a positively remodeled vessel.  The RR of the two groups exhibited an 
interesting and informative pattern that further differentiated stable and vulnerable 
regions, with large differences in the two groups at 3 months.  The 31% of the disrupted 
plaques started with an RR>1.05 (outward remodeled) at baseline, which increased to 
over 40% of the plaques by the last time point.  Only 24% of the non-disrupted plaques 
had a RR>1.05 at baseline and the distribution of RR for the non-disrupted segments 
remained nearly unchanged by the end of the experiment (Figure 15).  It is interesting to 
note that there is a significant fraction of segments that show positive remodeling at 
baseline (prior to experimental manipulation), which must represent a natural variation in 
the vessel wall of the rabbit, an issue that we have not previously explored.  The 
important finding here is that the disrupted plaques shows more segments with positive 
remodeling than the non-disrupted plaques. 
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Figure 15:  RR distribution of the two aortic segment types over time.  The higher 
RR distribution (>1.05) for the non-disrupted segments started at ~24% and 
remained about the same over the experiment’s time course.  This is in contrast to 
the increased RR>1.05 values seen for the disrupted segments, which started at 
about 30% at baseline, but increased to over 40% by the end of the experiment. 
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Figure 16 shows that there is a general increase in the uptake of the contrast agent Gd-
DTPA during atherosclerosis progression. Differences in the % increase of signal 
intensity between disrupted and non-disrupted plaques were seen at each month, but 
became significant at 3 months. The disrupted plaques showed much more signal 
increase from the baseline compared to the non-disrupted plaques at 3 month 
(75.51±13.77% vs. 31.02±6.45%, p=0.0022).  
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Figure 16:  Increase of Gd-CE from baseline over time.  The disrupted segments 
showed quickly increasing Gd-CE over time while the non-disrupted segments 
showed a much more subtle increase.  Statistical significance between the two 
groups was achieved at the 3-month time point (75.51±13.77% vs. 31.02±6.45%, 
p=0.0022).   
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The averaged numerical values for measurements of VWA, remolding ratio, and 
gadolinium enhancement for each MRI scan are presented in Table 2, Table 3, and Table 
4. 
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Table 2: Averaged Vessel Wall Area (VWA) Measurements over Time (mm2) 
 
Baseline 1 Month 2 Month 3 Month 
Non-disrupted 
Plaques 
(n = 142) 
7.90 ± 0.16 6.99 ± 0.13 6.30 ± 0.11 6.81 ± 0.13 
Disrupted 
Plaques 
(n = 39) 
8.25 ± 0.36 6.87 ± 0.24 6.99 ± 0.25 8.19 ± 0.43 
P-value 0.32 0.66 0.01 0.00 
 
Table 3:  Averaged Remodeling Ratio (RR) over Time 
 
Baseline 1 Month 2 Month 3 Month 
Non-disrupted 
Plaques 
(n = 142) 
0.99 ± 0.01 0.98 ± 0.01 0.97 ± 0.01 0.99 ± 0.01 
Disrupted 
Plaques (n = 39) 0.99 ± 0.02 1.00 ± 0.01 1.05 ± 0.02 1.04 ± 0.02 
P-value 0.73 0.26 0.00 0.02 
 
Table 4:  Average Increase in Gadolinium Enhancement over Time (%) 
 
1 Month  
/Baseline 
2 Month  
/Baseline 
3 Month 
/Baseline 
Non-disrupted 
Plaques (n = 142) 19.43 ± 3.04 34.17 ± 4.23 31.02 ± 6.45 
Disrupted Plaques 
(n = 39) 29.47 ± 5.56 49.44 ± 7.28 75.51 ± 13.77 
P-value 0.13 0.09 0.00 
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2.4 Discussion  
In this study, serial MRI was used to monitor the progression of atherosclerotic plaque in 
this rabbit model of atherothrombosis.  The rabbit model of atherothrombosis offers a 
remarkable window of opportunity to monitor noninvasively plaques that remain stable 
and plaques that disrupt after pharmacological triggering. The latter serve as a model for 
the highest risk, most dangerous plaques in humans. In our rabbit model of accelerated 
atherosclerosis with plaques mimicking most of the stages found in human disease [18], 
we found independent development of plaques that disrupt and plaques that do not 
disrupt within the same aorta.  VWA, RR and gadolinium uptake differentiated stable and 
vulnerable plaque segments as early as 2 months and became more pronounced at month 
3 in this experimental protocol, even after the rabbits were switched to normal chow.  
As discussed in reviews of unstable plaques, most characteristics of vulnerable plaques 
are derived from morphological studies.  More recently, there has been a necessary shift 
in clinical studies from morphological studies, to studies that focus on specific cardiac 
events as end points.  A clinical study using intravascular ultrasound (IVUS) showed that 
spontaneous cardiac events were often caused by lesions that were angiographically mild, 
thus raising the importance of the need for reliable markers of vulnerability [139].  
Another study showed the potential of virtual histology IVUS as a tool for identifying 
plaques that are at higher risk of causing a cardiac event [140].  Despite the many 
advances in the understanding of specific morphological and biological features, a 
compelling argument can be made that “advancing the field will require establishing 
relevant translational animal models that produce vulnerable plaques at risk for rupture” 
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[66]. The value of an animal model with plaque disruption is accentuated by the fact that 
the majority of human plaques with vulnerable features do not disrupt, and very long 
prospective studies are required to validate the in vivo characteristics of the highest risk 
plaques.  
The rabbit model used in our study provides not only an endpoint of disruption but 
advantages of observing different plaques types in the same aorta at the end of the 3 
month protocol when MRI mages are obtained [18].  Here, we applied our MRI 
diagnostic protocols to measure some hallmarks of high-risk plaques: VWA, RR and 
gadolinium uptake [24]. 
Measurement of VWA is a common approach to detect and monitor plaque burden 
without high resolution of plaque components. In our study, VWA exhibited a larger 
increase for disrupted plaques compared to stable plaque starting at 2 months in both the 
individual example (Figure 11) and the averaged data.  These data have been shown to be 
a high-risk feature in human lesions [141] and is in agreement with our previous work 
[24].  Of note is the pattern in which the VWA for both segment types is larger at the 
baseline time point, decreases after the surgery (at 1 month) and then continues to 
increase slowly over time.  This phenomenon is likely due to the endothelial damage of 
the balloon surgery.  Shrinkage of the vessel wall observed after ballooning is not 
unexpected based observations in pigs and in humans of extracellular matrix remodeling 
and collagen/elastin deposition after angioplasty and stenting [142, 143].  This is a 
natural healing response of the vessel wall after interventions that lead to in-stent 
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restenosis and vessel wall constriction. As the inflammatory processes begin and lipids 
accumulate, the plaque and vessel wall grows. 
On average, the RRs at 1 month remained at intermediate remodeling values 
(0.95≤RR≤1.05).  At 2 months, the disrupted plaques increased into the positive 
remodeling category (RR>1.05), while the non-disrupted plaques remained in the 
intermediate range.  Plaques that did not disrupt had similar RR values between 1 and 3 
months, while the plaques that disrupted were more likely to progress to an outward 
remodeled state (RR>1.05, Figure 15).  These results corroborate with our previous MRI 
findings at 3 months [24] and previous work using IVUS [63, 75, 140] and CT [73, 141], 
which showed an association between  plaque vulnerability and positive remodeling in 
animals and humans.  This difference in RR between the two types of plaques could 
signify an important pathological change that triggers/transforms a plaque from stable, to 
a plaque at high-risk for disruption.  Although this has been implicated in earlier studies 
without an endpoint of disruption [63], it is now directly tested and validated in this 
rabbit model. The early positive RR and increased VWA exhibited by the disrupted 
plaques suggest that plaque growth is a stimulating factor triggering outward remodeling 
at sites of future vulnerability to avoid luminal narrowing [144-146], which is in 
agreement with the inflammatory infiltrate and increased lipid content seen in 
histological studies of positively remodeled rabbit plaques in our model [18].  
Additionally, human studies have linked positive remodeling with increased macrophage 
content [147, 148] and increased plaque volumes [148, 149].  RR has been regarded as a 
late marker of plaque vulnerability; however, our results suggest that the RR can 
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potentially be used as an early marker of plaque vulnerable, thus helping clinicians decide 
which plaques to track as a patient’s disease progresses.  Additionally, the RR could also 
be used as an efficacy marker for the testing of therapeutics.   
Increased uptake of Gd-DTPA in the form of a circumferential or crescent shape (Figure 
11) has previously been demonstrated to be associated with plaque vulnerability in 
rabbits [24].  Our new data suggested that increased gadolinium enhancement for 
disrupted plaques was consistently higher than those seen in non-disrupted plaques and 
became significantly different at 3 months. In some specific examples (Figure 11), the 
comparison of signal increase was profound.  Increased inflammation, 
neovascularization, and decreased vessel wall integrity are likely culprits of the increased 
enhancement exhibited by the plaques that disrupted likely caused by over time [18].  
The gadolinium uptake patterns in this study are complementary to the results of other 
investigations that showed increasing Gd-DTPA uptake as the plaques progressed in both 
human [150, 151] and rabbit models [152] compared with little or no enhancement in 
healthy patients and control rabbits.  Primary component analysis has begun to be 
developed for the dynamics of gadolinium uptake within the vessel wall [78], showing 
focal heterogeneity differences between stable and disrupted plaques.  This data analysis 
technique is still being developed and will be outside the scope of this thesis.   
Inflammation is now recognized as a key pathology of all stages of atherosclerosis, but 
this finding shows that it may be a major driving force for thrombosis of plaques in the 
high-risk categories that can be determined by non-invasive MRI. Once inflammation 
starts, it can be a self-propagating process that continues, allow plaques to advance to 
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stages of higher risk, even after lowering cholesterol intake.  Our findings support 
conclusions that excessive remodeling is highly associated with plaque progression to 
higher vulnerability as seen in pig coronary models [63].  The correspondence of RR with 
higher gadolinium uptake supports the conclusion seen in the pig that the inflammation 
status of a plaque is a key factor in the progression of plaques to the high-risk category. 
The results of our study indicate that advanced plaques in a high state of inflammation 
could benefit from treatments with strong anti-inflammatory effects, such as have been 
reported in clinical trials that led to the conclusion that “inflammation may be an 
important driver of residual risk in patients with coronary artery disease despite 
aggressive statin therapy” [153].           
The rabbit provides an excellent model for early detection of high-risk plaque and allows 
systematic and controlled studies of therapeutics.  The potential for clinical translation is 
feasible because MRI measures features that are known to be characteristics of human 
plaques and our studies were performed on a clinical 3T scanner.  When combining 
multiple plaque vulnerability measurements of plaque burden, RR, and gadolinium 
uptake, the diagnostic accuracy is increased when compared to each individual 
measurement alone [24].  Our MRI protocol could be used to detect early/intermediate 
plaque disruption risk and lead to a new standard of care for diagnosing and monitoring 
of human atherosclerotic plaques.  
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2.5 Study Limitations 
The rabbit model used here cannot completely mimic atherosclerotic disease progression 
found in humans.  The balloon denudation and high cholesterol diet methods are used to 
accelerate plaque growth, but we have previously shown that this rabbit model exhibits 6 
well-characterized stage of human plaques [18].  Additionally, plaque disruption in this 
model was shown to occur mainly in plaques that shared several histological features 
known to be associated with vulnerable plaques in humans [18, 76].  Another limitation is 
the use of external pharmacological agents as a method for triggering plaque disruption, 
and the necessity for timed plaque disruption for our MRI analysis.  Although the exact 
mechanism for plaque rupture in humans has not been identified, studies point toward 
platelet activation and adhesion, and the release of vasoconstriction molecules as possible 
critical steps in the process [154].  Using this as a basis, our model uses procoagulant 
factor (viper venom) and a vasoconstriction agent (histamine) as plaque rupture catalysts. 
The thrombus is in our rabbit is platelet-rich with fibrin and collagen [155], 
characteristics of thrombus formation in humans. Furthermore, balloon injury and 
cholesterol feeding in the rabbit has recently been shown to replicate features of human 
thrombosis including tissue factor expression and its regulation by NF-kappa B [156, 
157].   
For potential clinical translation, a limitation of this study is the time needed for manual 
segmentation of the MR images.  However, some groups have reported the continuing 
development of automatic segmentation programs that show promise as a solution for this 
issue [158].  Additionally of note is that the methods used here were done for the 
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abdominal aorta of the rabbit, which, in humans, is generally not the main culprit of 
plaque rupture.  Only human studies of problem vessels (such as the carotid artery) can 
validate the methods used here as a viable diagnostic tool for the clinic.  
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2.6 Conclusions 
In this study, we showed that MRI can be used to visualize progressive atherosclerotic 
plaque development and discern plaque features associated with vulnerability (large 
VWA, positive remodeling, and increased gadolinium uptake) as early as 2 months in a 
rabbit model of atherosclerosis.  We believe the findings in this report demonstrate the 
feasibility of using MRI as a tool for assessing and monitoring high-risk plaques. The 
non-invasive nature of this modality makes it suitable for longitudinal evaluation of the 
disease in animal models and humans. Additionally, the monitoring of plaques in this 
particular rabbit model could serve as a preclinical platform for testing the efficacy of 
various therapeutics in not only reducing vulnerable plaque features, but also in reducing 
the occurrences of plaque ruptures, which is arguably the more important clinical 
outcome.  An unanswered clinical question is whether or not the reversal of vulnerable 
plaque features lead to a reduction of plaque ruptures.  Studies could be done using this 
animal model to test whether or not therapies that decrease vulnerable features lead to a 
decreased risk of plaque rupture.  
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Chapter 3:  Using MRI to determine the efficacy of Lipoxin A4 in 
reduction of plaque vulnerability. 
 
This chapter will be focused on Aim 2 of my thesis work. The goal of this work was to 
test the hypothesis that therapeutics that resolve inflammation, i.e. (resolvins, statins, and 
lipoxins) will decrease atherosclerotic plaque severity and plaque disruption when 
administered to rabbits in our standard atherosclerosis inducing protocol.  Our studies 
used Lipoxin A4 (LXA4) an endogenous anti-inflammatory molecule derived from the 
ω-6 fatty acid arachidonic acid [86].  A total of 20 rabbits were studied in 2 groups of 10.  
Each group underwent the same experimental protocol for induction of atherothrombosis.  
Our analysis to evaluate the effects of LXA4 was done with two different approaches and 
endpoints for one group, we used our conventional approach of thrombus verification via 
post trigger MR images and for the other group the aorta was cut longitudinally for en 
face staining of lipid content and direct visualization of the thrombus.  Not all animals 
had complete MRI data because of rabbit deaths and an instrument failure during the time 
of imaging in the approved protocol.  In spite of limitations, the work here stimulated 
discussion and reassessment of the protocol to observe the thrombus resulting from 
plaque disruption and provides evidence for beneficial effects of chronic administration 
of LXA4 as a therapeutic.    
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3.1 Significance  
Inflammation has been accepted as a major component of atherosclerotic disease [2, 3, 
159-161] after the earliest studies emphasized lipid and lipoprotein (LDL) contributions 
[1]. Although the exact mechanisms behind the progression of early, clinically silent 
lesions into late stage vulnerable lesions are still unclear; there has been a growing pool 
of evidence suggesting that unresolved inflammation of the vessel wall plays an 
important role in such progression [3, 4, 159]. It is important to emphasize that 
inflammation is a defense mechanism that is kept in check and halted by natural 
molecules including resolvins, lipoxins and other pro-resolution substances [162].  
Although the majority of therapeutic studies to date have focused on intervention of 
vessel stenosis and thrombosis [163-165], the clinical outcomes of patients given 
thrombolytic, anticoagulant and/or antiplatelet agents still yield a high rate (12-16%) of 
cardiac events within half a year from hospital discharge [166, 167].  With the less-than-
ideal clinical outcome of these treatments and the growing evidence that elevated 
inflammatory markers (in particular C-reactive protein) are associated with adverse 
clinical cardiac outcomes (irrespective of atherosclerotic burden) [168-170], it is no 
wonder that many groups have turned to more preventative pro-resolution of 
inflammation therapeutic methods to try and avert these dangerous cardiac events. 
Inflammation resolving molecules have been shown to be associated with a reduction in 
plaques [168, 171-175] with varying degrees of success.  However, it has been shown 
that early preventative treatments (use of these therapeutics prior to severe 
atherosclerosis) yielded a decrease in sudden death risk and coronary heart disease [176, 
	  	  
78 
177].  However, extended use of therapeutic agents may have adverse effects that are 
sometimes unpredicted and the use of endogenously produced anti-inflammatory 
molecules could alleviate these concerns.  Since LXA4 is an endogenously produced 
molecule that has strong pro-resolving actions and is currently in clinical trials, it is an 
ideal substance for this particular study [84, 87].  Lipoxins have been shown to reduce 
proinflammatory cytokine generation by macrophages in vitro [178] and transgenic 
rabbits that overexpressed lipoxins were protected against atherosclerosis [179].  In mice 
fed a high fat diet, the production of these lipid mediators is perturbed and thought to 
contribute to accelerated atherosclerosis [180].  With these findings as a rationale, this 
study aims to determine whether or not supplementation of LXA4 can produce 
atherogenic protection and, more importantly, result in a reduction of cardiac events 
(plaque rupture).   
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3.2 Methods 
Animal Model and Drug Administration 
This study used a total of 20 male NZW rabbits (H01-H20).  All rabbits received the 
same protocol to induce atherosclerotic and thrombosis described in detail in Chapter 2 
(section 2.2) [24].  Briefly, the rabbits were fed a high cholesterol diet for 8 weeks and 
then switched to normal rabbit chow for an additional 4 weeks.  Two weeks into this 12- 
week protocol, the animals received a balloon catheter surgery under general anesthesia.  
For the study in this chapter, 2 ligatures (a 3-0 silk suture) were placed around the second 
premolar of both mandibular quadrants) under isoflurane anesthesia at the start of the 12 
week protocol [181].  This ligature served as a drug administration route for the duration 
of the experiment.  An example image of what the ligature looks like is shown in Figure 
17 
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Figure 17:  Image of a ligature placed on the rabbit’s tooth.  This silk suture was 
used as a drug administration site. 
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The animals were divided into two groups, treated and untreated (each with n = 10).  The 
treated group received (8µg per ligature sight at a concentration of 1mg/ml in 10% 
ethanol) of LXA4 under on their ligatures 3 times a week during the entire 12-week 
atherosclerosis protocol, while the untreated groups received the same volume of 10% 
ethanol on their ligatures as a control. 
MRI of Study Rabbits 
The rabbits were imaged at the end of the 12-week protocol, triggered via the 
pharmacological process with RVV and histamine (as described in Chapter 2), and then 
imaged again 48 hours after the 3 month imaging session for post-triggered 
characterization of the aorta and thrombus detection.  The imaging sessions were 
performed in an identical manner to that described in Chapter 2, with the same scan 
sequences and scan parameters.  One circumstance of note is that the entire 
atherosclerotic protocol and the treatment portion of this experiment were performed at 
the Forsyth Institute (Cambridge, MA).  At the end of the 12-week atherosclerotic 
process, the animals were transferred to Boston University (Boston, MA) for the MRIs 
and pharmacological triggering processes.  Figure 18 shows this particular experiment’s 
timeline. 
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Figure 18:  Experimental timeline.  Rabbits were fed a high fat diet for 8 weeks, 
with a balloon injury surgery performed at week 2 of the diet.  The rabbits were 
then switched to normal chow for an additional 4 weeks.  During this 12-week 
protocol, the rabbits were given their treatment (LXA4 for the treated group and 
ethanol for the untreated group) 3 times a week.  All rabbits are then imaged, 
triggered and then imaged again. 
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Image Analysis 
The MR images obtained from this set of experiments were analyzed using the same 
methods described in Chapter 2.  Once ROIs were manually segmented, calculations 
were made using Equations 2.1-2.5.  Quantitative information obtained from our scan 
sequences included the VWA, RR and signal intensity increase via gadolinium uptake 
and were obtained from these images identically as described in Chapter 2.  One major 
experimental difference of note here is the classification method used.  In Chapter 2, we 
separated plaque segments based on the disrupted and non-disrupted criterion.  However, 
in this experiment, there were two separate groups of rabbits:  treated and untreated.  
Hence, for data comparisons, we divided the data into two classifications:  treated and 
untreated. 
Histology  
For the first 10 rabbits (5 treated and 5 untreated, H01-H10), the aortas were prepped for 
histology as previously described (Chapter 2).  Once fixed, the samples were cut into 2 
cm long segments and cryosectioned in 10 µm thick slices throughout the length of each 
sample.  For each in vivo MRI slice (4mm thick), a set of slides of the corresponding 
aortic segment was collected.  Essentially, one set of slides was collected for every 4mm 
of aortic tissue.  Once collected, the samples were stained with hematoxylin and eosin 
(H&E) stain. 
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En Face Tissue Preparation and Image Analysis 
For the second set of rabbits (5 treated and 5 untreated), after the experimental protocol 
was complete, we elected to perform en face analysis prior to histology.  First, the aortic 
samples were removed from the animals as described in Chapter 2.  Then, the samples 
were stretched to their in vivo lengths and preserved in 10% formalin overnight.  The 
samples were then cut into 2 cm segments. 
For the en face tissue staining, the aortic segments were cut open longitudinally and 
pinned down to reconstruct the aorta to its full length (see Figure 28 for reference).  In a 
dissection tray, the pinned aortas were soaked in an oil red o staining solution to stain for 
lipids.  The samples were then washed with ethanol and images were taken with a sample 
camera. 
Once stained, the high lipid content areas of the aorta are stained deep red, while the 
normal aortic tissue remains its natural color.  Images were analyzed manually using 
ImageJ (NIH).  The en face images were loaded the ROIs were drawn around the entire 
aortic sample as well as around each red (diseased) aortic area.  An example of one 
segmented sample is shown in Figure 19.  
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Figure 19:  Example image of manual segmenting diseased aortic areas.  The 
smaller yellow ROIs that encircle the red areas represent individual diseased areas 
(Ad) while the ROI encircling the entire sample represents the total vessel area 
(Atotal).  The percent of aortic area stained (Astained) is then calculated using Equation 
3.6. 
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The percent of diseased area was then calculated using Equation 3.6. 
A!"#$%&' = A!A!"!#$ 
Equation 3.6:  Calculation for the % of area stained red (diseased aortic area 
Astained) where Ad is the area of each stained area of the aorta and Atotal is the total 
area of the vessel. 
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3.3 Results 
As summarized in Figure 20 and Figure 21, 2 groups of rabbits   (H01-H10 and H11-
H20) were studied at different times.  Each group contained 5 treated and 5 untreated 
rabbits.  In the first set of rabbits (H01-H10, Figure 20), post-trigger MR images were not 
obtained for 4 of the untreated rabbits due to the MRI machine malfunctioning.  Results 
will be presented in multiple forms [either as both groups combined (H01-H20), or as 
each set separately (H01-10 or H11-H20)]. 
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Figure 20:  Flow chart of data analysis for the first set of rabbits (H01-H10).  Here, 
the rabbits were split into two groups, treated and untreated.  In the treated groups, 
all animals received the post-trigger MRI scans and their aortas’ were extracted for 
histology.  In the untreated group, H06 received the post-trigger MRI, but an MRI 
malfunction caused H07-H10 to miss their post-trigger scans.  All aortas’ for the 
untreated group were also used for histology. 
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Figure 21:  Flow chart of data analysis for the second set of rabbits (H11-H20).  
Here, the rabbits were split into two groups, treated and untreated.  In the treated 
groups, H13 died prior to the post-trigger MRI, while the remaining animals 
received the post-trigger scan.  In the untreated group, H16 died prior to the post-
trigger scan, while the remaining animals received their post-trigger scans.  In this 
second set of rabbits, the post-trigger images were unreliable in thrombus detection 
and we elected to do an en face analysis of the aortic samples to visual detect 
thrombus formation.  
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First data from all animals (H01-H20) will be compared as treated vs. untreated groups.  
Our results presented in this way (Figure 22, Figure 23 and Figure 24) show no statistical 
difference in the mean VWA, the mean of the normalized contrast enhancement or the 
mean RR between the treated and untreated groups.  The mean of the normalized contrast 
enhancement and the mean of the RR were similar for both groups, but for the VWA the 
treated group was larger (no statistical significance, Figure 22). 
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Figure 22:  Mean vessel wall area (VWA) of the two experimental groups (n=20) 
obtained from pre-trigger images.  The data show no statistical difference between 
the two groups in mean VWA area.  Data shown are mean ± SD. 
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Figure 23:  Normalized contrast enhancement signal intensity of the two 
experimental groups (n=20) obtained from the pre-trigger images.  The data show 
no statistical difference between the two groups.  Data shown are mean ± SD. 
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Figure 24:  Mean remodeling ratio (RR) of the two experimental groups (n=20) 
obtained from the pre-trigger images.  These data were calculated by taking all RR 
values from each group and averaging them.  The data show no statistical difference 
between the two groups.  Data shown are mean ± SD. 
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Treatment Shifts Remodeling Ratio Distribution  
This section also summarizes data obtained from all rabbits (H01-H20). As discussed 
below, the accepted “standard” cut off for outward remodeling is based on early studies 
with IVUS and histological features of vulnerability, whereas our studies are based in 
defining vulnerability as a plaque that disrupts after triggering. Therefore, we analyzed 
data for individual rabbits, and used different cutoff values.  Since the majority of 
segments in each animal are non-disrupted segment, averaging all of the data can mask 
differences between the two groups of rabbits.  Therefore, we decided to view the data 
presented here on a per segment per animal basis.  First we compared the % of segments 
having a RR above 1.05 or 1.13 in each animal and averaged that data (Figure 25); the 
untreated animals had a larger % of the higher RRs, which is suggestive of higher 
vulnerability.  Additionally, when looking at the RR distributions in the two groups 
across all animals (Figure 26), it can be seen that the treated group, overall, had lower 
RRs with the distribution shifted left of the distribution of the untreated group.  The 
treatment animals were less likely to have this higher RRs (RR>1.05 or RR>1.13) as 
compared to the untreated animals and that there may be outliers present (H13, Figure 
27), indicating that the shift in RR may be larger than shown in Figure 26. 
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Figure 25:  Average percentage of segments with RR>1.05 or RR>1.13 in each 
group.  Here, the percentage of segments with RR>1.05 or RR>1.13 for each rabbit 
was calculated and then the average of the means were calculated in each group 
(treated and untreated).  Data shown are mean ± SE. 
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Figure 26:  Remodeling ratio (RR) distribution of treated and untreated rabbits.  
The treated group has a slightly more left skewed distribution. 
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Figure 27:  Percentage of RR>1.05 and RR>1.13 in each animal.  As shown, the 
treated group had fewer RR>1.05 and even fewer RR>1.13.   
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En Face Analysis Shows No Statistical Differences in Overall Lipid Contents 
Qualitatively, the en face images of stained aortic samples (H11-H20) show that the 
treated group had two severe cases of atherosclerosis (H13 and H14, Figure 28) while the 
untreated group had three severe cases (H18-H20, Figure 29).  Figure 30 shows a 
disrupted plaque (with thrombus seen) for both treated and untreated animals (Figure 
30B) and shows what the best expected outcome was (Figure 30A) by removing what 
may be deemed as outliers if more animals are added and do show a major difference 
between treated and untreated animals.  The quantitative values for the percentage of 
aortic area stained by the Sudan Red stain for lipids for each animal and for the means of 
each group can be seen in Figure 31 and Figure 32, respectively.  These data indicate that 
treatment seems to reduce the overall percentage of diseased aortic area (not statistically 
significant).  
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Figure 28:  En face images of the treated group aortas stained with Sudan Red.  H13 
and H14 have severe cases of atherosclerosis in which nearly the entire aorta is 
stained.  Aortas that had an attached thrombus upon longitudinal excision are 
labeled as “Disrupted” (H13).  
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Figure 29:  En face images of the untreated group aortas stained with Sudan Red.  
H18, H19 and H20 have severe cases of atherosclerosis in which nearly the entire 
aorta is stained. However, the Sudan red stains for lipid, and this may be fatty 
streak and not advanced plaque.  Aortas that had an attached thrombus upon 
longitudinal excision are labeled as “Disrupted” (H19 and H20).   
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Figure 30:  Figure of aortic samples that were the best expectation for the 
experiment.  A) Shows relatively healthy tissues in the treated group if H13 and H14 
are omitted, while the untreated group has much more plaque disposition if H17 is 
omitted.  B) H13 (treated) and H16 (untreated) both had plaque disruption with an 
attached luminal thrombus as shown above. 
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Figure 31:  Percentage of aortic area stained red for each individual animal. 
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Figure 32:  The mean of the percentage of area stained red for each group of 
animals.  Data are presented as mean ± standard error. 
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Plaque Rupture Occurrences in Each Group  
Thrombus associated with plaque disruption was viewed in two different ways i) by using 
en face visual verification by opening the aortic sample (H11-H20) and ii) by using post-
trigger images to find thrombi as described in Chapter 2 (H01-H06 and H11-H20), as 
summarized in Figure 20 and Figure 21.  Using the MRI data for detecting thrombus 
(H01-H06 and H11-H20), there was little difference between the percent of animals that 
had ruptures in the treated (n=9) vs. the untreated group (n=5).  Note that it was not 
possible to obtain the post trigger MRI for visualization of thrombus in 4 of the untreated 
animals (H07-H10, MRI malfunction); hence the smaller number of untreated rabbits in 
this comparison. With all data averaged, both groups had a rupture rate of about 50-60% 
(Figure 33).  However, when cross-examining the MRI verification thrombus method 
with the en face thrombi visualization method (treated n = 5 and untreated n = 5), there 
were mismatches in information.  H11, H12, H14 and H15 all showed plaque rupture via 
MRI, but no thrombi were seen in the en face examination.  The difference between the 
in vivo MRI results and the visual exam could be explained by the fact that the post 
trigger MR images lacked the usual clarity as summarized in Figure 20 and Figure 21 and 
led to an over estimation of thrombi.  The results of this mismatch can be seen in Figure 
5. 
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Figure 33:  The percentage of animals in each group that present with plaque 
rupture when using the existence of a thrombus via MRI as the main criterion (n=5 
untreated and n=9 untreated).   
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Figure 34:  Percentage of animals that present plaque rupture when categorized 
with en face verification of thrombus existence.  Each group had a sample size of n = 
5.  
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Table 5:  Mismatch in MRI and en face visualization of plaque rupture (existence of 
thrombus).  N/A indicates that the data are not available.  By default, if either the 
MRI or en face data are missing, then the Mismatch column will have N/A as a 
comparison is not possible. 
 
 
 
 
 
 
 
  
Animal Rupture?	  (MRI) Rupture?	  (Cut	  Open) Mismatch?
H11 Yes No Yes
H12 Yes No Yes
H13 N/A Yes N/A
H14 Yes No Yes
H15 Yes No Yes
H16 N/A No N/A
H17 No No No
H18 No No No
H19 Yes Yes No
H20 Yes Yes No
Thrombus	  Existance	  Table
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Histology Shows Morphological Differences between Plaques 
In comparing the histology of the two animal groups, H & E staining showed differences 
in vessels that were heavily outward remodeled and had much thicker vessel walls as 
compared with thinner, healthier looking aortic tissue.  However, there were examples of 
both healthy and severely diseased tissue in both treated and untreated groups (Figure 
35).  Below is an example of a healthy treated animal aorta (Figure 35A), a severely 
diseased treated animal aorta (Figure 35B) and a severely diseased untreated animal aorta 
(Figure 35C).  The healthy treated tissue shows a thinner vessel wall, minimal plaque and 
a dense collagen network (blue) and a nice fibrous cap (purple) lining the plaque (Figure 
35A).  In contrast (Figure 35B), the severely diseased tissue in the treated animal shows a 
much thicker vessel wall, a diffuse collagen network (blue), a thinner fibrous cap (as 
indicated by the light purple tone surrounding the plaque luminal wall).  Furthermore, the 
plaque is larger and more diffuse.  In the untreated, unhealthy tissue (Figure 35C), an 
even thicker vessel wall is observed, with a very diffused and eccentric plaque.  Also 
notice that the lumen area is filled with red blood cells (clotted blood).  This comparison 
shows individual variation in the rabbit’s response to therapy. 
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Figure 35:  Histology samples from treated (A and B) and untreated (C) animals.  
Samples were stained with H&E. 
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3.4 Discussion 
This study used the inflammation resolving LXA4 in a chronic treatment regime in 
rabbits with accelerated atherothrombosis.  We observed significant individual variations 
in the rabbits, both treated and untreated groups, and the small number of animals 
investigated here did not yield statistical differences between the two groups, but showed 
promise in the effects of the LXA4.  In our labs previous study in this same rabbit model, 
Phinikaridou et al. found that using an RR cut off value of 1.05 yielded vulnerable plaque 
prediction with a sensitivity of 67.8% and a specificity of 77.6% [24].  For example, there 
were no observed statistical differences in the mean RR between the two groups of 
animals in both trials. However, this averages a wide variation in both individual rabbits, 
and plaques.  On closer scrutiny of the data, a histogram of RR values on a per segment 
basis averaged for all rabbits suggested that treatment shifts the RR to lower values.   The 
histogram distribution with the treated group occupies more of the lower range of RRs 
(Figure 3.8).  Additionally, when viewing the mean of the percentage of segments in each 
animal that has a RR>1.05 or 1.13 (with RR>1.05 being considered a feature of plaque 
vulnerability [24, 73, 140, 141], the treated group has a lower occurrence of the more 
severe remodeling values as shown in Figure 25.  Currently, there are no studies to 
suggest that these higher remodeling rations translate to increased plaque vulnerability 
(higher RR translating to more vulnerability), but the higher RR indicate the vessels 
greater need to compensate for luminal narrowing [144-146].  This greater luminal 
narrowing could indicate a site of accelerated plaque growth, which may translate to a 
more vulnerable lesion.  This data suggests that the use of LXA4 reduces atherosclerotic 
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plaque’s overall ability to recruit lipids and expand the lesion site, which is in accordance 
with LXA4’s anti-inflammatory properties [84, 87-89].  This reduction in diseased tissue 
is also observed in the treated en face images Figure 28.  
In this study using en face thrombus existence as the criterion, the treatment group shows 
fewer thrombi and therefore a diminished rate of rupture.  Although the number of 
animals is low (n=5 for each en face group), this reduction is still a promising result for 
the value of the therapy.  If this trend were to hold when additional animals are added to 
this study, then LXA4 could be shown as being able to reduce clinical events (ruptures).  
This result corroborates with other findings that used Candesartan (an angiotensin 
receptor blocker) in this same animal model and showed a reduction in macrophage 
accumulation (reduction in inflammation), which correlated to reduced plaque rupture 
rates in the treated group [182].  Additionally, Dwyer et al. shows that by using marine n-
3 fatty acids, it was possible to inhibit leukotriene-mediated inflammation that leads to 
atherosclerosis, adding to growing confidence of the effectiveness of anti-inflammatory 
interventions for atherosclerosis [171].   
Of concern for this particular set of experiments is the mismatching observed in 
identifying the existence of thrombi seen by MRI or visually verified en face.  A previous 
study in the lab has shown that post-trigger MRI had a high accuracy of plaque rupture 
detection [24], which raises the question of this experiments debacle.  Since this 
mismatch was seen only in the treated group, it could be that the treatment had 
physiological effects on the rabbits which deviates from the settings that the MR scans 
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were set up for.  Of course, it could just be that these scans in particular were bad scans 
and that we were unlucky. 
The current data set does not contain statistical differences between the treated and 
untreated groups in any of the parameters measured in this experiment.  However, there 
are some trends of note that lead us to believe that additional study animals would add 
statistical power to the experiment. 
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3.5 Study Limitations 
The limitations in this experiment include those mentioned about the rabbit model 
(Chapter 2) previously.  Additionally, when viewing the results with an eye to future 
clinical applications, the occurrence of a clinical event (rupture) is arguably the most 
important parameter to consider when evaluating the efficacy of treatment.  However, in 
this model, the plaque rupturing process is pharmacologically triggered.  Although the 
process itself is performed to mimic actual plaque rupture (as mentioned in Chapter 2), 
how this particular rupturing process alters the efficacy of the treatment cannot be 
evaluated.  It is possible that the plaque triggering process obscures the effects that the 
treatment may have had in stabilizing the plaque.  The balloon surgery in out protocol 
could also have a similar consequence [47].   
Another limitation is the time duration of treatment was given.  Our atherosclerotic 
protocol was designed and optimized to produce advanced plaque lesions and plaque 
rupture at an accelerated rate (3 months).  This protocol may diminish the potential 
benefits that the anti-inflammatory treatment, thus preventing proper resolution of 
advanced plaque lesions.  One consideration for future studies would be to reduce the 
number of passages of the balloon catheter in the endothelial damage surgery and/or to 
reduce the cholesterol feeding to mitigate the severity of the masking effects of the 
protocol on the treatment efficacy.    
Non-model limitations include the limited number of animals used. To date, only 10 
rabbits have been subjected to the en face analysis (5 each group), and only 14 animals 
had complete MRI data.  Additionally, of those 14, at least 4 had mismatch rupture 
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verification compared to en face observations, which we believe originates from lower 
quality images that tended to over report ruptures.  More data mismatch between the MR 
images and actual tissue analysis may have occurred, but we do not have en face data for 
H01-H10 to verify this. There is also a large variation in atherosclerosis “vulnerable 
plaque in individual rabbits”. We have noted in previous studies that about 47% of 
rabbits with our protocol do not have a plaque disruption, whereas some rabbits have 
several disrupted plaques [24].  It is therefore not surprising that there is a variation and 
individual response of the rabbits in the treatment group.  Additionally, with the small 
sample size presented here, compounded by topical application of the substance and 
measuring the systemic effects, it is expected that results would be as such.  
Also of note, is the RR calculation itself.  Current techniques use a reference lesion 
within an animal to normalize all other values within that same rabbit (namely the outer 
vessel wall area) to generate a RR for each segment of the aorta.  Although this has 
worked well in the past, the treatment of animals may require that this parameter be 
redefined.  If a treated animal has one lesion (the reference lesion) that is especially 
healthy due to treatment, then the RR of the rest of the vessel may be expressed as overly 
remodeled (a higher RR).  Conversely, if a diseased animal has an entire aorta of diseased 
tissue, then the reference lesion would be a diseased segment as well, possibly leading to 
lower RRs than exists.  The study, as presented here uses plaque rupture (a clinical event) 
as an end point to mitigate possible convolutions that may arise from such data analysis.   
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3.6 Conclusions 
In this study, we showed that treatment with LXA4 had a nominal, albeit non-statistically 
significant, effect on the RR; en face diseased aortic area; and possibly plaque rupture 
rate of the atherosclerotic rabbits.  Although the mean RR between the treated and 
untreated groups did not show any statistical differences, the histogram of RRs shows 
that the treated group had a distribution profile in which fewer, more severe (higher) RRs 
were present.  The en face data suggested, qualitatively, the treatment helped prevent 
lipid accumulations (as evidenced by the lower mean percentage of aortic area covered 
with red stain), which would translate to a decrease in plaque progression.  Finally, when 
analyzing plaque rupture rates with visual verification (en face experiments, rabbits H11-
H20), the treated group showed only one rupture compared to the untreated group’s two 
ruptures.  Due to the low number of animals in the study (MRI malfunction and half en 
face half histology), it is not possible to make any definitive claims.  However, the results 
presented here give confidence in the future of this work and provides compelling 
preliminary data for grant applications. 
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Chapter 4:  Developmental work on theranostic ultrasound contrast 
agents (microbubbles) 
 
The work presented here serves as a proof of feasibility for theranostic agents that could 
be used in the detection and treatment of a variety of diseases and treatments.  The idea is 
to create a vehicle that possesses the ability to be tweaked to be loaded with different 
drugs, to be targeted to different disease states and to contain contrast for different 
imaging modalities.  Specifically for my work, there is potential for using a theranostic 
MRI contrast agent in conjunction with targeted microbubbles for improved plaque 
detection and treatment as well.  The work presented this chapter demonstrates the 
feasibility and proof-of-concept of developing theranostic contrast agents. 
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4.1 Significance 
In addition to MRI, ultrasound has shown some promise in the future for vulnerable 
plaque prediction.  Although ultrasound has a lower resolution than MRI, it provides the 
benefits of low cost and widespread availability.  Ultrasound alone does not provide 
much information about plaques; however, the robustness and tenability of ultrasound 
contrast agents provide a strong starting point for the development of ultrasound-based 
diagnostics.  Specifically, lipid microbubbles have shown promise in this area due to 
biocompatibility and tenability.   
Microbubbles are gas-filled spheres with a shell that can be composed of phospholipids, 
polymers or a variety of other substances [183, 184].  When exposed to US, these 
microbubbles undergo alternating contraction and expansion, a process known as 
cavitation, due to the compressibility of the encapsulated gas when subjected to acoustic 
pressure [185-187].  These vibrations cause the microbubbles to return a greater amount 
of US signal to the transducer, as compared to the practically incompressible surrounding 
tissues.  This difference in signal return accounts for the majority of the contrast provided 
by microbubbles in conventional grey scale ultrasound imaging [188].  Although there 
are many other methods of obtaining contrast using microbubbles (Doppler [189] and 
contrast specific imaging [185] among others),  the physics underlying these methods are 
beyond the scope of this chapter. 
A key advantage of microbubbles is that they can be loaded with drugs [190-193], bound 
with targeting moieties and only attached specific sites [192-194], and that they have 
even been shown to release their contents when exposed to ultrasound [195].    
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4.2 Methods (Drug Incorporation and Ultrasound Stability) 
Di-acetylene Lipid Preparation 
Polymerizable Di-acetylene (DA) lipids with 5k-poly ethylene glycol (PEG 5K) was 
obtained from a collaborator in solid form.  The compound was dissolved in chloroform 
(Sigma-Aldrich) to a concentration of 5.36µM, which has been found to be optimal for 
microbubble formation in previous lab experiments.  Then 1 ml of the solution was put 
into a scintillation vial (Wheaton, NJ).  Using a vacuum oven (Shel Lab), the mixture was 
heated to 40C under vacuum to pull off the chloroform.  When the lipid has been dried 
down, it forms a thin film and 1 ml of 5/5/90 (5% glycerol, 5% propylene glycol, and 
90% DI H20) was added into the vial with a magnetic stir bar and stirred on a hotplate 
(Fischer Scientific Thermix) at 60C for 1 hour.  After allowing the lipids to disperse into 
the 5/5/90 solution, the mixture was bath sonicated (Branson) for up to 3 hours, until the 
mixture was clear, which results from the formation of liposomes.  When the solution 
was clear, it was ready to form bubbles in the microfluidic devices.  Previous lab 
experiments determined that the current best concentration of DA lipids to use is 25%, so 
we will be focusing on characterizing and testing this particular microbubble formulation.     
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Microfluidic Device Prep 
The same method used in our lab has been thoroughly in the literature.  Using AutoCAD, 
a lab member created a flow-focusing microfluidic device by refining a device design 
found in the literature [124].  The device is shown in Figure 36.  The entire device is 8-
10µM in depth and the other important dimensions are as follows:  lipid mixture channels 
were 50um in width, gas channel was 35µM in width, and the orifice was 2µm.  
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Figure 36:  Microfluidic flow-focusing device schematic.  The continuous flow of 
lipids and gas meet at the orifice to form a monodisperse population of 
microbubbles. 
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Then, using a DWL66 mask writer (Heidelberg Instruments, Heidelberg, Germany) with 
a 10mm write head (resolution of 1µm) in a class 100 cleanroom, a mask was made on a 
resist-coated chrome mask (Nanofilm, West Lake, CA).  After the 5 hour writing process, 
the mask was developed for 2 minutes using AZ300MIF developer (AZ Electronic 
Materials, Somerville, MA) and then placed in chromium etchant 1020 (Transene 
Company Inc., Danvers, MA) for another 2 minutes.  Upon completion of this process, 
the residual resist was stripped in an 1165 resist stripper (Rohm Haas, Marlborough, MA) 
for 30 minutes at 70C.  To ensure complete resist removal, the mask was rinsed with 
water then scrubbed with non-abrasive cotton swabs dipped in acetone.  The mask was 
then inspected under a microscope to ensure it was of acceptable quality.  Finally, a triple 
rinse (acetone, methanol and isopropanol) was performed.  When the mask was 
completed, the microfluidic device wafer stamp can be made. 
In a class 1000 clean room, we use a 100 mm diameter silicon wafer (University Wafer, 
Boston) and cleaned it with Piranha solution (sulfuric acid and hydrogen peroxide) over a 
3-hour period to remove any manufacturing caused impurities.  The wafer was then 
dehydrated at 95C for 5 minutes.  The wafer was then placed on a Delta 80 RC/T3 
Spinner (Suss, Garching, Germany) and SU8-2005 (MicroChem, Newton, MA) was 
applied to it.  The wafer was then spun at 1000rpm for 2 minutes in order to obtain a 
10um layer of SU8-2005.  The wafer was then baked at 95C for 2-3 minutes and exposed 
using a MA6 Mask Aligner (Suss Microtec, Garching, Germany) for 60 seconds on CH2 
with soft contact parameters.  After exposure, the wafer was placed in SU8 developer 
(MicroChem, Newton, MA) for a minute and rinse with DI water and dried under 
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nitrogen gas.  Now the wafer is ready to be used to make polydimethylsiloxane (PDMS) 
stamps of the microfluidic devices. 
The silicon wafer was coated with silane by placing a 10ul drop of (heptafluoropropyl) 
trimethylsilane, 97% (Sigma, St. Louis, MO) into a Petri dish next to the wafer and 
placing both under vacuum overnight.  After being treated, Sylgard 184 PDMS (Dow 
Corning, Midland, MI) in a 10 to 1 ratio was poured over the wafer in the Petri dish (the 
wafer was placed pattern side up so that the PDMS would mold around the SU8 pattern 
and for the device).  The Petri dish was then placed into a vacuum to remove bubbles 
(degas).  The remaining bubbles are popped using a 23-gauge needle.  Finally, the Petri 
dish with the degased PDMS/wafer combination is placed into an oven at 80C for at least 
2 hours to cure the PDMS. 
Once cured, PDMS molds were cut out and peeled off of the wafer and appropriate holes 
were punched under a laminar flow hood (NuAire, Plymouth, MN) punched using a 
0.75mm diameter Harris Uni-core hole-punch (Sigma, St. Louis, MO).  To avoid 
exposure to contaminants, the PDMS stamps were brought to a clean room for glass 
binding.  The stamps were cleaned using a triple rinse and then dried under nitrogen.  In 
order to have the PDMS devices bind to glass, they (along with the glass slides) are put 
into a Plasma Asher (PVA TePla, Corona, CA) for 3 minutes using high oxygen flow.  
The stamps were then placed design side down onto the glass slide and allowed to bond 
in an 80C oven overnight. 
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Flow-focusing and Bubble Generation 
In order to create hydrophobic surfaces within the device channels for complete wetting, 
the stamps were plasma treated in a Harrick PDC-32G Plasma Cleaner (Harrick, Ithaca, 
NY).  Then the input portholes were fitted with polyethylene tubing (Becton Dickinson, 
Franklin Lakes, NJ).  The device was then placed under an Axiovert 25 microscope 
(Zeiss, Oberkochen, Germany) and attached as follows:  the Decafluorobutane gas 
(Synquest Laboratories, Alachua, FL) was attached to a pressure regulator and passed 
through a pressure meter and a 0.2µM filter before entering the device; the lipid solution 
was put into a 1ml syringe and connected in series with a 0.2µm pore size syringe filter 
(Corning, Corning, NY), a 23 gauge dispensing needle (McMaster-Carr, Elmhurst, 
Illinois), and tubing.  To have precise control of the flow rates, a syringe pump PHD2000 
Harvard Apparatus (Harvard Apparatus, Holliston, MA) was used and operated between 
0.4-2um/min to generate desired bubble sizes.  Similarly, the gas pressure was controlled 
to be between 4-18psi.  The two flows were turned on and allowed to flow to the orifice 
for bubble creation.  Using a high-speed camera (Photron, San Diego, CA), the device 
orifice was viewed and while gas and lipid flow rates were varied to produce desired 
bubble sizes.  Once the bubbles are created, they are collected through the two output 
ports via a pipet tip.  The collected bubbles are then placed into a well of a 96 well plate 
and polymerized with a germicidal 30W T8 UV lamp (General Electric, Fairfield, CT) 
with a peak wavelength of 254nm.  
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Drug Loading of Microbubbles 
For drug incorporation Fluorescein isothiocyanate (FITC) labeled paclitaxel was mixed at 
a 1% mole ratio with label free paclitaxel.  The resulting mixture was then immersed in 
the 25% DA lipid mixture in 5/5/90 at a 40% mole ratio. 
Drug Loading Verification 
In order to verify drug loading in the microbubbles, we used a fluorescence-enabled 
microscope to image the microbubbles in Bright-Field, and then again under the 
wavelengths that the FITC labeled paclitaxel was active in (495 nm/519 nm for 
excitation/emission). 
Microbubble Stability Testing 
To test the stability of microbubbles under ultrasound, we prepared one large batch of 
microbubbles (non-drug loaded, 25%DA with PEG 5k) and separated the microbubbles 
into three equal volume groups.  One group was left unpolymerized (non-polymerizable 
shelled microbubble, NSM), one group was polymerized under UV for 10 minutes and 
the final group was polymerized for 60 minutes.  The microbubbles were then fixed into a 
poly acrylamide gel and exposed to a 3.5 MHz US insonation for 1 minute.  Before and 
after US exposure, the microbubbles were imaged within the gel under a microscope.   
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Stability Analysis 
Multiple images of the microbubbles before and after ultrasound insonation were taken 
via Bright-Field microscopy.  To analyze these data, the number of bubbles in an area 
were counted before and after insonation.  Then, the after value was divided by the before 
value and multiplied by 100 to obtain the % bubbles remaining.  This was done for 
multiple locations and then values were averaged. 
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4.3 Results (Drug Incorporation and Ultrasound Stability) 
Ultrasound Stability 
By comparing the number of bubbles seen before and after insonation for the three 
groups of microbubbles (non-polymerized, 10 minute polymerized and 60 minute 
polymerized), we were able to determine that the stability of these particular 
microbubbles were dependent upon the length of polymerization time.  After 1 minute 
under ultrasound insonation, the non-polymerized bubbles were reduced to ~10% of the 
original population.  In contrast, the 10 minute polymerized bubbles were able to retain 
~27 percent of their original population and the 60 minute polymerized bubbles were 
most stable with an over 80% retention rate.  This data are shown in Figure 37 as mean 
with standard deviation for error bars. 
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Figure 37:  Percent of microbubbles remaining after one minute of ultrasound 
insonation.  The trend shows that the longer the microbubble formulation was 
polymerized, the stronger the microbubble’s stability against bursting under 
ultrasound. 
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Drug Loading Verification 
When taking Bright-Field (BF) and FITC images of the drug loaded microbubbles, we 
were able to show that the FITC-labeled paclitaxel showed up on the shell of the 
microbubbles, thus verifying that the drug was indeed in the microbubble shell (Figure 
38). 
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Figure 38:  The BF image (left) shows the location of the two microbubbles imaged 
here.  Then FITC image (right) shows the location of the FITC-labeled paclitaxel.  
As seen here, the drug is located within the microbubble shell, indicating that they 
were incorporated into the microbubble successfully. 
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4.4 Discussion (Drug Incorporation and Ultrasound Stability) 
The results of this experiment showed that the percent of bubbles remaining after US 
exposure can be tuned based on polymerization time.  This allows for an array of possible 
bursting profiles to be tested based on simply changing polymerization time of the 
microbubbles.  This result was important in that it provides a platform for tuning drug 
release profiles based on polymerization time and has implications on the development of 
multiple burst drug delivery methods.  Additionally, the pilot work indicates this method 
can incorporate at least certain drugs (in this case paclitaxel) into the lipid membrane, 
making this a feasible medium for a theranostic vehicle. 
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4.5 Methods (Oil Droplet)  
Fabrication of Microfluidic Devices 
Soft lithography techniques were used to generate patterned silicon wafers and 
microfluidic PDMS devices as described in section 4.2.  The device design was modified 
by Park et al. [196] from Hettiarachchi et al. [197].  The hydrophobicity of the surface of 
the PDMS device was verified by means of a contact angle goniometer (Kruss DSA100, 
Hamburg, Germany).   
Liposome Dispersions 
The lipid mixture containing 25 mol% of polymerizable diacetylene lipids, N-(5’-
hydroxy-3’-oxypentyl)-10-12-pentacosadiynamide (h-Peg1-PCDA) and N-
[methoxy(polyethylene glycol)-5000] - 10-12-pentacosadiynamide (m-Peg5000-PCDA) 
(10 mol% h-PEG1PCDA and 15 mol% m-PEG5000PCDA) (NanoValent 
Pharmaceuticals, Inc., Bozeman, MT), and 75% of L-α-phosphatidylcholine, 
hydrogenated Soy (hydro soy PC) (Avanti Polar Lipids, Alabaster, AL) was used for the 
25 DA lipid mixture.  The lipids were dissolved in chloroform and resuspended in 
10/10/80 (10% glycerol, 10% propylene glycol, 80% DI water) as described in section 
4.2. 
The non-polymerizable lipid formulation was made in a similar manner, but with a molar 
ratio of 85% of 1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC) (Avanti, 
Alabaster, AL) and 15% 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-5000] (DSPE-PEG5K) (Avanti, Alabaster, AL).   
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Incorporating Doxorubicin in Oil 
Doxorubicin hydrochloride (Sigma-Aldrich, St. Louis, MO) was added to DI water and 
then neutralized with the addition of sodium hydroxide (NaOH) to form a doxorubicin 
precipitate.  The solution was then centrifuged at 2,500 rpm for 5 min, and the 
supernatant was removed.  The remaining solution was dried under vacuum, and the 
doxorubicin powder was then weighed and dissolved into filtered (0.2µm syringe filter) 
glyceryl triacetate (Sigma-Aldrich, St. Louis, MO).  
Oil-in-Water Emulsions via Vortexing and Flow-focusing 
Two methods were employed for the generation of drug encapsulated oil droplets: 
vortexing and flow-focusing.  Flow-focused oil droplets were made in a similar manner 
as described in section 4.2, with the doxorubicin infused oil replacing the gas (Figure 36).  
For the vortexed droplets doxorubicin infused oil and the lipid mixture was placed into an 
Eppendorf tube and vortexed at level 5 for 30 sec on a Baxter Scientific Vortex Mixer 
S8223-1 (Deerfield, IL).  The polydispersity, σ, was calculated as σ = δ/davg × 100%, 
where δ is the standard deviation and davg the average droplet diameter.  
Stability Tests 
Triacetin oil droplet stability was measured in buffered saline to compare the effects of 
choice of fabrication method and lipid shell polymerization. Both polymerizable 25DA 
lipids and the non-polymerizable 85/15 DSPC/DSPE PEG-5K formulations were used in 
parallel to compare the effect of polymerization on droplet stability.  Three groups of oil 
droplets were used to compare stability: 25 DA polymerized, non-polymerized 25 DA, 
and the 85/15 DSPC/DSPE PEG-5K as a control. Each oil droplet formulation was held 
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constant at a ratio of 1:10 (v:v) oil:lipids. Polymerization of the 25 DA polymerized 
droplets was performed in the Spectrolinker Xl-1000 with a cumulative UV energy of 0.5 
J/cm2 at a wavelength of 254 nm.   
Each group was collected after fabrication (equal volume collections of 25 µl) and 
suspended into 175 µl of 150mM NaCl at pH 7 and mixed for a total volume of 200 µl.  
Stability was measured as the percent of droplets remaining over time.  The number of 
droplets over a constant area was counted using a hemocytometer and normalized by the 
number of droplets over the same area at time zero. At each time point, the solution was 
manually shaken, from which 15 µl was placed onto a hemocytometer. Three random 
sections were imaged at 10X using a phase contrast microscope (Axiovert S25, Zeiss, 
Oberkochen, Germany) and a high-speed camera. Images were taken at 0 min, 30 min, 1 
hr, 2 hr, 3 hr, 4 hr, and 5 hr, and droplets were counted manually using ImageJ. Statistical 
analysis was performed on the percentages calculated from the images (n = 3) taken at a 
given time point. A two-tailed unpaired Student’s t-test, with α= 0.05, was used to 
compare the differences between fabrication methods for a given lipid formulation (flow-
focused vs. vortexed). Likewise, the percentage of oil droplets remaining was compared 
among lipid formulations for a given fabrication method using ANOVA and a subsequent 
post hoc Tukey’s range test.   
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4.6 Results (Oil Droplet) 
Size Distribution and Encapsulation of Doxorubicin 
The two populations of oil droplets were both qualitatively and quantitatively different.  
The flow-focused droplets had an average diameter of 11.1 µm (σ = 8.81%) while the 
vortexed droplets had a much more polydispersed population with a mean diameter of 
15.0 µm (σ =83.2%).  Both populations were visible under Tetramethylrhodamine 
(TRITC) filtered fluorescence microscopy (557/576 nm excitation/emission spectrum), 
indicating that both populations indeed contained doxorubicin.  Qualitatively, it can be 
seen that the vortexed population is indeed much more polydispersed than the flow-
focused population (Figure 39).   
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Figure 39:  Bright-Field and TRITC filter fluorescent images of doxorubicin-
encapsulated micro-oil droplets produced by microfluidic flow-focusing (left) and 
vortexing (right) methods. 
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Stability of Oil Droplets 
The data shows that microfluidic produced oil droplets were more stable against 
dissolution than the vortexed counterpart (when comparing identical compositions of 
lipids and oil components).  Additionally, polymerization of the lipid outer shell provided 
even more stability when compared with the same formulation of lipids and oil.  The 
most stable form of the oil droplets was the polymerized flow-focused droplets.  In flow-
focused droplets, the lipid formulation seemed to play a small effect on stability as 
evidenced by the increased stability seen in the 25DA lipid population compared to the 
flow-focused 85/15 population.  However, in vortexed populations there seemed to be no 
differences in stability with changes in lipid shell composition (Figure 40). 
   
	  	  
137 
 
Figure 40:  Comparison of the effect of fabrication method and polymerization on 
droplet stability in 150 mM NaCl pH 7. Triacetin oil droplets were fabricated using 
either microfluidic flow-focusing (FF), denoted by a solid lines, or by vortexing (V), 
denoted by dotted lines. Error bars represent the standard deviation in the percent 
of oil droplets remaining at each time point and an (*) represents p values of < 0.05 
when comparing FF to V for each lipid formulation. 
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4.7 Discussion (Oil Droplet) 
The results presented here show that microfluidic produced oil droplets exhibited 
increased stability compared to vortexed droplets.  We postulate that the microfluidic 
formed droplets had a more uniform lipid packing density on the surface than the 
vortexed droplets, thus providing them with stability.  Furthermore, this packing density 
possibly plays a major role in the added stability that polymerization provided.  There 
may be a minimal packing density in which polymerization could occur effectively, as 
indicated by the extra stability of polymerization only being observed in the flow-focused 
droplets.  
Vortexing produced a higher number of droplets than flow-focusing because it created 
large number of small droplets, from sub-micron to 5 µm. Overall, the vortexed 
population had a higher surface to volume ratio (as created by the uncountable sub-
micron droplets) causing increased burden on the available surfactant pool, thus 
decreasing the overall lipid packing density of the droplets (as compared to the uniform 
flow-focused droplets).  Additionally, the wide size distribution is known to cause 
Ostwald ripening, a phenomenon in which small particles dissolve and redeposit on the 
surface of larger particles.  This is compounded by the relatively great solubility of 
Triacetin oil in water (70 g/L).  This phenomenon is shown by fitting the data to Equation 
4.7, which describes Ostwald ripening when diffusion is limited. 
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R! − R!! = 8γC!v!D9R!T t 
Equation 4.7: The average particle size, <R>3, is linearly proportional to time, 
where, <R>03 is the initial mean number droplet radius, γ is the surface tension of 
the oil-water interface, c∞ is the molecular solubility of the solute, υ is the molar 
volume of the solute, D is the diffusion coefficient of the solute, T is the absolute 
temperature, and Rg is the molar gas constant. 
Oil droplets produced by flow-focusing did not show size changes over time, with the 
values of <R>3 - <R>03 near zero, whereas the ones produced by vortexing increased 
approximately linearly to time.  
Several studies mention that emulsions with >80mol% oil are not stable.  This suggests 
that a 10-20 mol% of phospholipids is necessary to maintain stability.  However, in this 
study, a 1 mol% lipid composition was used to create a stable oil in water emulsion via 
microfluidic flow-focusing.  These results are attractive in pharmaceutical applications in 
which higher emulsifier concentration levels can often be toxic and cause unwanted side 
effects. 
  
	  	  
140 
4.8 Study Limitations 
A major limitation of flow-focusing microbubble fabrication is the ability to scale up the 
process and produce sufficient volume of the contrast agent for clinical use.  However, 
some groups have experimented in parallel flow designs [198-200] and shown (scaled up 
production, but still small scale) that increased generation can be accomplished.  
Unfortunately, there has yet to be a method for larger scale (production scale) generation 
of product.  Additionally, the studies cited use simple droplet or microbubble 
formulations (no drug encapsulation, no targeting moieties, etc.) and more complex 
formulations could create further difficulties. 
Drug Incorporation and Ultrasound Stability 
Limitations of this particular set of experiments include the difficulty in making drug 
incorporated microbubbles and the variability in microbubble size creation, among 
others.   
Although for each experiment, the microbubbles produced are essentially monodispersed, 
it is difficult to reproduce the same-sized microbubbles (using the same device design, 
but different PDMS device) on a day-to-day basis.  Even though the lipid flow rate and 
gas pressure input are controlled via a pressure regulator and a syringe pump, using the 
same settings one day as opposed to a different day would not yield the exact same sized 
microbubbles.  Fortunately, this variation in size was not of orders of magnitude different 
(usually the sizes ranged from 3-10 microns in diameter), but this phenomenon still 
warrants consideration when designing future experiments.  Multiple factors could play a 
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role in these observed differences including lipid viscosity (although formulated and 
processed the same each time, small unknown variations could change this [lighting, 
temperature etc.]) the exact binding of the PDMS devices to the glass slides they are on, 
and even the angle at which the feeding tubes are inserted into the device. 
When making the paclitaxel incorporated microbubbles via microfluidic flow-focusing, 
the lipid-drug solution often caused device clogging, more so than lipid formulations in 
the absence of drugs.  Although this occurrence and issue was not fully investigated, it is 
also of consideration. 
Oil Droplets 
The limitations in this set of experiments include the method of stability measurement 
and the size differences (although with less deviation) created with the same parameters 
as described in the microbubble production using flow-focusing. 
Between the time lapsed readings of the oil droplets on the hemocytometer, the solutions 
are shaken to minimize sampling error (i.e. pipetting out a portion of the solution that just 
happens to have more/fewer oil droplets).  However, this shaking itself may play a role in 
droplet stability (agitation could cause droplets to coalesce).  Additionally, when placed 
into the hemocytometer, 3 images are taken at random of that time point and these images 
are used to count the number of droplets present.  This method of randomly taking 3 
images per time point also lends itself to error (pictures taken happen to be of an area 
with more/fewer droplets). 
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4.9 Conclusions  
The work presented here lays the groundwork for future studies involving microfluidic 
flow-focusing of drug encapsulated microbubbles.  In the Drug Incorporation and 
Ultrasound Stability portion of this work, experimentation has shown the viability of 
these microbubbles as stable drug carriers.  The Oil Droplets section also detailed why 
the use of flow-focusing is preferred (increased stability) even without considering the 
increased echogenicity provided by a monodisperse population of microbubbles.  With 
these few limited studies, there are a myriad of pathways that can be explored.  
Specifically of interest would be to test the ability of these formulations to release drugs 
and the effects of these drug-loaded bubbles on cells under ultrasound exposure and in 
the absence of such exposure.  Additional work on these processes has been performed 
by others in the lab. 
  
	  	  
143 
Chapter 5:  Summary, Future Directions and Final Thoughts 
 
5.1 Summary of Findings 
1. Chapter 2:  Serial MRI to Track the Progression of Atherosclerosis   
i. MRI was used to qualitatively show the increase in gadolinium contrast 
enhancement and increased remodeling ratio of plaque segments as 
atherosclerotic plaque lesions progressed. 
ii. Quantitative MR image analysis showed that plaque lesions that 
subsequently led to rupture had a higher remodeling ratio and a larger 
vessel wall area than plaques that do no rupture.  This difference is 
statistically significant at both the 2 and 3-month time points in the 
protocol. 
iii. At 3 months, gadolinium derived contrast enhancement was substantially 
greater in plaques that eventually disrupt compared to plaques that 
remained stable. 
iv. As the disease progressed, the plaques that eventually disrupt showed a 
shift from moderate remodeling ratios (<1.05) to higher remodeling 
ratios, while the stable plaques had nearly no shift in remodeling ratio. 
2. Chapter 3:  Using MRI to determine the efficacy of A4 Lipoxin in reduction of 
plaque vulnerability 
i. Mean vessel wall area of treated group was larger than that of the 
untreated group (not statistically significant). 
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ii. There was no discernable difference in the mean remodeling ratio and the 
mean contrast enhancement parameters between the two groups. 
iii. When viewing only larger remodeling ratios (RR>1.05 and RR>1.13), 
there is a marked difference between the two groups.  The treated animals 
had fewer aortic segments with the more severe RRs. 
iv. Treatment with lipoxin A4 shifted the RR distribution left (smaller 
values), thus reducing the amount of outward remodeling that is occurring 
in the vessel. This decrease in outward remodeling could be because the 
treatment reduced aortic stenosis, thus making less outward remodeling 
needed. 
v. En face analysis of aortas showed an overall decrease in atherosclerotic 
tissue in treated group, and fewer luminal thrombi. 
vi. Rupture rates are decreased with treatment when using visual verification 
method for detecting the existence of thrombi. 
vii. Histological findings indicate that treatment may not affect the entirety of 
an animal’s disease state, but possibly reduces the chances of an animal 
developing more severe plaques. 
3. Chapter 4:  Developmental work on theranostic ultrasound contrast agents 
(microbubbles) 
i. Preliminary data shows that microbubbles can be tuned to burst or not 
under ultrasound by varying the polymerization time of the diacetylene 
lipids. 
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ii. Labeled paclitaxel was successfully incorporated into the lipid 
microbubble shell showing promise in theranostic agent development. 
iii. Microfluidic flow-focusing was found to generate more stable drug-
encapsulated oil droplets than vortexing methods do.  These droplets can 
be stabilized further with polymerization of the outer lipid layer; however, 
the vortexed generated droplets are unable gain this additional stability.  
This is possibly due to the lipid packing density differences that may be 
exhibited between the two groups of droplets. 
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5.2 Future Directions 
1. Chapter 2:  Serial MRI to Track the Progression of Atherosclerosis   
i. Translation of findings to human studies – Additional data from this 
study supported our previous work and publications that MRI can detect  
plaques at high risk for disruption  The ideal end result of this research 
would be to test if these MR derived parameters would be as predictive if 
translated into human studies.  Some effort was made in performing MRI 
on patients scheduled for carotid endarterectomies; however, the sample 
size was small and patients receiving this surgery do not have plaques that 
necessarily produce rupture.  The criterion for this surgery is based on 
vessel stenosis.  A longitudinal time series of MRI would be ideal for 
tracking the progression of natural atherosclerosis. 
ii. Dynamic contrast enhancement data analysis – Gadolinium 
enhancement as measured by increased pixel intensity at a fixed time 
served as an indicator of progression of a plaque to a site of high 
vulnerability and could be valuable for monitoring therapies. This scan 
sequence was performed on the majority of rabbits presented in this thesis, 
as well other projects and obtaining software to analyze the dynamic 
contrast enhancement data (rate of gadolinium uptake into the vessel wall) 
could provide additional, possibly pivotal, information on plaque 
vulnerability.  The increased permeability of gadolinium has been 
associated with more damaged and inflamed vessel walls, which are 
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attributes of vulnerability [78].  Additionally, some preliminary analysis 
done in the lab showed that plaques that eventually rupture exhibited a 
much faster uptake of gadolinium than plaques that do not rupture (data 
not shown). 
iii. Endothelial shear stress analysis – Low endothelial shear stress has been 
identified as a feature of plaque vulnerability [201] and it is of interest to 
see whether or not this particular parameter occurs before or after initial 
lesion formation.  This data analysis can also be performed (the data has 
been collected), once proper analysis programs are obtained. 
iv. Improve remodeling ratio calculation – Issues have been pointed out on 
the validity of the remodeling ratio as a feature of plaque vulnerability.  
Although it has been a solid parameter in measuring plaque vulnerability 
and is used extensively in the literature, there are some concerns that need 
to be addressed.  The choice of a reference lesion, as done in our study, is 
sometimes flawed in that the reference lesion could be have significant 
atherosclerotic plaque and possibly outward remodeled itself, thus causing 
all other remodeling ratios to be attenuated even though the vessel could 
be heavily remodeled.  Future studies could use non-atherosclerotic 
regions of the aorta as a reference lesion (areas outside of the balloon 
injured area) or possible the mean outer wall area as the reference.  This 
parameter would have to be explored in depth. 
	  	  
148 
v. Reduction of MR scan times – The amount of time require per animal 
per scan currently is 1-2 hours depending on the scan sequence used.  This 
causes an increase in experimental costs, and less viability for clinical 
translation.  Currently, one limiting factor for scan time is the use of 
cardiac gating for reduction of motion artifacts.  The main issue is that the 
equipment used to read the animal’s pulse is made for humans.  Future 
experimentation should be done with an animal specific pulse reading 
device to ensure increased motion attenuation and decreased scan times. 
vi. Automated segmentation of data – The manual segmentation and 
analysis methods are repetitive, and can be completed using a preset 
program.  The main issue preventing such a process is segmentation of the 
vessel wall.  The contrast that MR provides between the lumen, the vessel 
wall and the surrounding adventitia is not sufficient for automatic 
segmentation based on pixel intensity.  A more complex (beyond the 
scope of my research) method must be employed to achieve such 
segmentation.  The automation of this process is required if it were to be 
translated into the clinic.  Currently, to image and analyze one rabbit at 
one time point would require a person a few days to complete, which is 
much too slow for clinical applications. 
2. Chapter 3:  Using MRI to determine the efficacy of A4 Lipoxin in reduction of 
plaque vulnerability 
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i. Increase study size – The addition of animals to this study could provide 
the statistical significance needed to have compelling evidence of 
atherosclerotic reduction with lipoxin use.  The current data shows 
promise in the therapeutic, but does not provide statistically significant 
data on the reduction of plaque vulnerability. 
ii. Increase treatment time – For this particular rabbit model, accelerated 
atherosclerosis is achieved via balloon surgery and high fat feeding.  This 
protocol is only used for a 3-month period, which may not be enough time 
for the lipoxin to repair the damaged aorta and resolve injury induced 
inflammation.  A future study in which the rabbits are given the balloon 
surgery, but fed a less severe high fat diet for a longer period of time with 
the lipoxin treatment could produce more favorable results. 
iii. Test lipoxin in a different model – The balloon injury and 
pharmacological trigger methods used here may confound the effects of 
the lipoxin.  The triggering process attempts to mimic actual rupture 
conditions, but there is no way to extract how this process effects actual 
treatment.  An alternative mouse knockout model could be used to see if 
anti-inflammatory treatment reduces cardiac deaths long term.  
iv. Serial MRI – By using serial MRI (as in Chapter 2) on treated and 
untreated animals, we would be able to track the effects of therapy over 
time.  
	  	  
150 
3. Chapter 4:  Developmental work on theranostic ultrasound contrast agents 
(microbubbles) 
i. Test drug loading capacity and release profile – Although we were 
successful in incorporating paclitaxel into the microbubble, we have yet to 
test the release profile and whether or not encapsulation of the drug made 
it less cytotoxic.  
ii. Lipoxin encapsulation – Testing the ability to encapsulate and release an 
anti-atherogenic drug/molecule would be the next step for the totality of 
this thesis work.   
iii. Microbubble formation in parallel – Upscaling the methods of flow-
focusing via parallel device creation would increase the production of 
microbubbles. 
iv. Test effects of polymerization on contrast – Since polymerization of the 
lipid shell changes the material properties of the microbubble, we expect 
there to be changes in the echogenicity of the microbubbles.  An 
experiment to test the difference between polymerized and non-
polymerized bubbles would be informational on these effects.  
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Final Thoughts and Suggestions (Aims 1 & 2) 
The results  in Aim 1 provide two major conclusions :  i) MRI is able to qualitatively and 
quantitatively ascertain features of atherosclerotic plaque segments over time and ii) 
some of these features are more prominent in vulnerable (ruptured) plaques.  Beginning 
at 2 months, MRI measures of vulnerability were evident, persisted and generally became 
more evident at 3 months.  These features were not present in stable plaques.  Reliable 
differences were seen both in individual plaques and after averaging all plaques with this 
binary categorization of stable and vulnerable.  With these results in mind, we expected 
the results from Aim 2 to show fewer vulnerable features in the treated animals.  
However, when comparing the % increase in contrast enhancement, the vessel wall area 
and the remodeling ratio of the treated rabbits vs. the untreated rabbits, there were no 
statistically significant differences.  This section of the thesis will focus on why these 
results may have arisen as well as touch upon some additional data analysis that can be 
performed that may resolve the contradicting results.  Finally, a suggestion for how future 
experiments for testing Lipoxin’s effects on plaque vulnerability will be discussed. 
Possible Causes of Unexpected Data Outcomes 
The unexpected outcome of data analysis seen in Aim 2 can first be attributed to the 
different data analysis (grouping methodology) used in Aims 1 & 2.  In Aim 1, the entire 
12 rabbit population was treated as one group.  Once the rabbits have undergone the 
entire 12-week protocol, plaque segments (MRI image slices obtained at 12 weeks, and 
prior to triggering) were categorized as either vulnerable by the functional endpoint of 
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plaque disruption with a luminal thrombus (ruptured after triggering) or stable (not 
ruptured after triggering).  Of note is the fact that a single rabbit may possess all stable 
plaques, all vulnerable plaques or a combination of both plaque types.  However, in Aim 
2 the two separate groups of rabbits were categorized as a whole (either treated or 
untreated) whereas in Aim 1 vulnerable plaques were grouped separately from stable 
plaques.  In Aim 2, a treated rabbit may possess both stable and vulnerable plaques (the 
same can be true for the untreated rabbits).  Therefore, a comparison of the two groups as 
treated and untreated could potentially mask effects that Lipoxin may have had on plaque 
vulnerability.  Theoretically, we would only expect Lipoxin to have measurable effects 
on vulnerable plaques and that stable plaques would have minimal changes due to 
treatment.  Hence, when finding the mean values of data within a treated rabbit, where 
the majority of plaque segments are stable (~80% according to data in Aim 1), it can be 
postulated that the values of these stable plaques mask the effects of Lipoxin on the 
vulnerable plaques.  Therefore, when comparing a treated rabbit to an untreated rabbit, 
the mean values are weighted towards the stable plaque populations within each animal 
group.  This phenomena may be a possible explanation as to why the measurements of 
vulnerability (remodeling ratio, vessel wall area and contrast enhancement) were not 
statistically different between the two groups. 
Another possible reason for the incompatible data seen in Aim 2 lies in the experimental 
protocol followed in Aim 2.  It is important to note that the experiments performed in 
Aim 2 served multiple purposes.  The primary purpose was to elucidate the effects of 
Lipoxin on plaque vulnerability.  However, we also had future experiments in mind 
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involving P. gingivalis and periodontal disease (P. gingivalis will be placed on the 
ligatures to invoke periodontal disease), which is why the ligature delivery method was 
used in Aim 2.  This drug delivery method may have affected the efficacy of the Lipoxin 
on plaque vulnerability. 
When placed upon the ligatures around the rabbits teeth, the Lipoxin must first enter the 
digestive pathway (stomach à large intestines à small intestines etc) before it is 
absorbed into the bloodstream by the body.  During this process, the Lipoxin will have 
been exposed to a variety of different, potentially altering, environments including the 
highly acidic stomach.  Additionally, to be absorbed into the blood stream fats (in 
general) are dissolved by bile (produced by the liver) to pass through the cells of the 
mucosa and then reconstituted into their original form prior to going into the lymphatic 
system and then into the bloodstream via veins of the chest.  Although there is no 
evidence that Lipoxin would follow such a pathway, the pathway described is one that 
the majority of fats follow and being a fatty acid, it would not be unreasonable to assume 
that Lipoxin would have a similar pathway.   
Due to the exposure to the acidic environment of the stomach and the bile interactions 
required for absorption into the lymphatics and then the bloodstream, it is possible that 
some of the Lipoxin may not be transported into the blood stream.  Additionally, the 
processes described could also alter the functionality of the Lipoxin.  Although the 
literature on these processes and how they affect Lipoxin specifically are limited, a study 
using a similar molecule, resolvin, has shown that delivery via ligatures decreased 
systemic inflammation markers (interleukin-6 and C-reactive protein) in a rabbit model 
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[1].  Although levels of resolvin in the bloodstream were not measured directly, the 
decrease in inflammatory markers after resolvin dosage via the ligatures suggest that at 
least some resolvin made it into the bloodstream.   
Additional Data Analysis Techniques (Aim 2) 
In order to resolve the data analysis differences discussed above, a couple of different 
data analysis techniques can be performed.  First, if we remove the stable plaques from 
the data set; that is, only compare the vulnerable plaques in the treated and untreated 
animals; we would be able to remove the complication that occurs from the fact that the 
majority of plaques within a given rabbit is stable.  In fact, when performing this analysis 
for the first 6 rabbits of Aim 2 (9 treated (35 segments) and 1 untreated, 14 
SEGMENTS), as shown below the mean vessel wall area, the remodeling ratio and the 
total contrast enhancement for the vulnerable plaques in the treated animals trend lower 
values than those for the vulnerable plaques in the untreated rabbits (Figure 41, Figure 
42, and Figure 43).  This suggests that Lipoxin has an effect in the anticipated direction 
on the vulnerable plaques.   
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Figure 41:  Mean values of the vessel wall area of the vulnerable plaque segments in 
the treated and the untreated groups (p-value = 0.483 for a 2-tailed t-test, indicating 
no statistical significance). 
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Figure 42:  Mean values of the total contrast enhancement of the vulnerable plaque 
segments in the treated and the untreated groups (p-value = 0.000 for a 2-tailed t-
test, indicating statistical significance between the two groups). 
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Figure 43:  Mean values of the remodeling ratio of the vulnerable plaque segments 
in the treated and the untreated groups (p-value = 0.335 for a 2-tailed t-test, 
indicating no statistical significance). 
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Another consideration involves the non-statistical differences seen in the rupture rates of 
the untreated vs. the treated group (Chapter 3).  This is most likely a result of the low 
sample size used in this work, in which case a traditional t-test statistic would yield non-
significant results.  A t-test would provide information on whether or not the mean of the 
two populations (treated vs. untreated) are different; however, this measure is more 
valuable as the variation within each population is lowered.  Therefore, the larger the 
sample size, the more valuable a t-test becomes, assuming that the two populations tested 
are indeed different.  This specific test statistic may not have been the most effective 
measure when viewing the effects of Lipoxin on plaque rupture rates.  A more relevant 
statistical measure may have been the Chi-square test of Independence [2], which would 
provide insight on whether or not a variable is independent of another variable.  In this 
case, we would want to test if the existence of a plaque rupture is independent of 
treatment (meaning that treatment has no effect on plaque rupture). 
To perform a Chi-square test for the data presented here, we would first need to 
determine the variables and place them into a contingency table as shown in Table 6.  
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Table 6:  Contingency Table for Chi-squared Testing 
 
  
Treated Group Untreated Group
Number of Rabbits 
with Rupture A B
Number of Rabbits 
without Rupture C D
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Here, the values are tabulated such that A = number of rabbits with a plaque rupture 
within the treated group, B = number of rabbits with a plaque rupture within the untreated 
group, C = number of rabbits without a plaque rupture within the treated group, and D = 
number of rabbits without a plaque rupture within the untreated group.  With these data, 
it would be possible to test the independence of one variable upon another.  For this 
particular case, to test if rupture outcome is independent of treatment, we would perform 
the following calculation: 
𝜒2 = 𝑂 − 𝐸𝐸  
Where X2 is the chi-squared value, O is the observed number of ruptures and E is the 
expected number of ruptures.  To perform this analysis with the ‘data’ in Table 6, first a 
table of expected values is to be constructed.  These expected values (E) are values of the 
expected outcome, IF treatment is not associated with plaque rupture.  Here the expected 
value of each variable are calculated as follows: 
𝐸 𝐴 = 𝐴 + 𝐵(𝐴 + 𝐵 + 𝐶 + 𝐷)×(𝐴 + 𝐶) 
𝐸 𝐵 = 𝐴 + 𝐵𝐴 + 𝐵 + 𝐶 + 𝐷 × 𝐵 + 𝐷  
𝐸 𝐶 = 𝐶 + 𝐷𝐴 + 𝐵 + 𝐶 + 𝐷 × 𝐴 + 𝐶  
𝐸 𝐷 = 𝐶 + 𝐷(𝐴 + 𝐵 + 𝐶 + 𝐷)×(𝐵 + 𝐷) 
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Once the expected value of each case has been determined the 𝜒2 can be calculated.  In 
this case, for A (number of ruptured rabbits in the treatment group) it would be: 
𝜒2 = 𝐴 − 𝐸(𝐴)𝐸(𝐴)  
Then, using the 𝜒2 distribution tables, we can obtain the probability that rupture rates are 
independent of treatment.  Here, a p-value < 0.05 would indicate that the probability of 
having A number of ruptures in the treatment group is < 0.05 if we assume that there is 
no relationship between treatment and rupture rate.  If this were the case, then the 
hypothesis that there is no relationship between treatment and ruptures is unlikely to be 
true and we can assume that the two variables are not independent of each other. 
Suggested Future Experimental Protocol for Lipoxin Rabbit Study (Aim 2) 
To increase the certainly of the data interpretation of data for Aim 2 (determining the 
effects of Lipoxin on plaque vulnerability), it would be ideal to change all non-related 
parameters to directly test this hypothesis. 
To do this, the experimental protocol performed in Aim 2 must be altered.  In a future 
study, two changes in the study design can be made.  First, there is the issue of dosage.  
An experiment in which a set of rabbits are separated into different groups and received 
different dosages of the Lipoxin would be necessary to determine the dose effects of the 
molecule on atherosclerosis.  Once an appropriate dose has been determined, then testing 
the differences between treated and untreated animals can be performed. In this new 
experiment, the two groups of rabbits (treated and untreated) would undergo the same 
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atherosclerotic protocol with high cholesterol diet and balloon catheter injury.  However, 
the treated animals will receive the new dosage (determined by the dose experiment) and 
the untreated group will receive the ethanol placebo control.  This experiment could also 
forego the ligatures and inject the Lipoxin directly into the rabbit bloodstream and 
thereby remove all effects of delivery method on Lipoxin effectiveness.  Additionally, as 
we have information regarding the time at which vulnerable features occur from Aim 1, 
these animals would also be monitored over-time with serial MRI, beginning at least at 8 
weeks.  Another valuable addition to our protocol  would be to perform blood tests on the 
rabbits at 2-week intervals to determine the amount of free flowing Lipoxin as well as 
measure some markers of inflammation (including the well-known C-reactive protein )  
to follow the inflammatory state and treatment state of the rabbits. 
By using conditional mean values (only counting the vulnerable plaques within each 
group) and different statistical methods (McNemar’s test) on the current data set, we may 
be able to show more definitively that the Lipoxin treatment does indeed effect plaque 
vulnerability.  However, even with these additional analysis, it is still advisable to 
perform more experiments (either to increase the number of animals to Aim 2 or a 
completely different set of animals in a study that only aims to determine the 
effectiveness of Lipoxin on reduction of vulnerability) in order to remove experimental 
uncertainties. 	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